Malaria molecular surveillance in the Peruvian Amazon with a novel highly multiplexed

Plasmodium falciparum Ampliseq assay

Johanna Helena Kattenberg[a#], Carlos Fernandez-Miñope[b,c], Norbert J. van Dijk[a,1], Lidia

Llacsahuanga Allcca[b], Pieter Guetens[a], Hugo O. Valdivia[d], Jean-Pierre Van geertruyden[c], Eduard

Rovira-Vallbona[a], Pieter Monsieurs[a], Christopher Delgado-Ratto[b,c], Dionicia Gamboa[b,e], Anna

Rosanas-Urgell[a]

[a]Institute of Tropical Medicine Antwerp, Biomedical Sciences Department, Antwerp, Belgium

[b]Instituto de Medicina Tropical "Alexander von Humboldt", Universidad Peruana Cayetano

Heredia, Lima, Peru

[c]Global Health Institute, University of Antwerp, Antwerp, Belgium

[d]Department of Parasitology, U.S. Naval Medical Research Unit No 6 (NAMRU-6), Lima, Peru

[e]Departamento de Ciencias Celulares y Moleculares, Facultad de Ciencias y Filosofía,

Universidad Peruana Cayetano Heredia, Lima, Peru

Running Head: Pf AmpliSeq assay for malaria molecular surveillance

address correspondence to: ekattenberg@itg.be and arosanas@itg.be

[1] Present address: N.J. van Dijk, Department of Medical Microbiology, Amsterdam University

Medical Centers, Amsterdam, the Netherlands

[2] Present address: Barcelona Institute for Global Health, ISGlobal, Barcelona, Spain

Abstract

Molecular surveillance for malaria has great potential to support national malaria control programs (NMCPs). To bridge the gap between research and implementation, several applications (use cases) have been identified to align research, technology development, and public health efforts. For implementation at NMCPs, there is an urgent need for feasible and cost-effective tools.

We designed a new highly-multiplexed deep sequencing assay (Pf AmpliSeq), compatible with benchtop sequencers, allowing for high accuracy sequencing at higher coverage and lower cost than WGS, targeting genomic regions of interest. The novelty of the assay is in its high number of targets multiplexed in one easy workflow, combining population genetic markers with 13 near full-length resistance genes, applicable for many different use cases. We provide a first proof-of-principle for *hrp2* and *hrp3* deletion detection using amplicon sequencing. Initial sequence data processing can be performed automatically, and subsequent variant analysis requires minimal bioinformatic skills using any tabulated data analysis program.

The assay was validated with a retrospective sample collection (n = 254) from the Peruvian Amazon between 2003 and 2018. By combining phenotypic markers and a within-country 28-SNP-barcode, we were able to distinguish different lineages with multiple resistant (*dhfr/dhps/crt/mdr1*) haplotypes and *hrp2* and *hrp3* deletions, increasing in recent years. We found no evidence suggesting the emergence of ART-resistance in Peru. These findings indicate a parasite population under drug pressure, but susceptible to current antimalarials, and demonstrates the added value of a highly multiplexed molecular tool to inform malaria strategies and surveillance systems.

Importance

While the power of next generation sequencing technologies to inform and guide malaria control programs has become broadly recognized, integration of genomic data for operational incorporation into malaria surveillance remains a challenge in most malaria endemic countries.

The main obstacles include limited infrastructure and accessibility to high-throughput sequencing facilities and the need for local capacity to run in-country analysis of genomes at a large enough scale to be informative for surveillance. In addition, there is a lack of standardized laboratory protocols and automated analysis pipelines to generate reproducible and timely results useful for relevant stakeholders.

With our standardized laboratory and bioinformatic workflow, malaria genetic surveillance data can be readily generated by surveillance researchers and malaria control programs in endemic countries, increasing ownership and ensuring timely results for informed decision and policy-making.

Introduction

The Global Technical Strategy for Malaria 2016-2030 identified the use of high-quality surveillance data for decision-making as an essential pillar for malaria elimination (1). In view of current challenges to malaria control (*e.g.* spread of drug resistance, changing transmission intensity, risk of malaria importation in malaria-free areas, and RDT-failure), genetic epidemiology is increasingly recognized in its

potential to inform national malaria control programs (NMCPs). By aligning multiple scientific fields in
support of NMCP priorities, 'use cases' were specified creating scenario's where genetic surveillance can
be informative to decision-making (2, 3), and can be used to develop and implement new technologies.

Molecular markers associated with drug resistance are reliable predictors of treatment responses (2, 4,
5), can provide warning for emerging resistance, guide treatment policies (6), and even replace
therapeutic efficacy studies in low malaria transmission areas (4, 5, 7, 8). The value of these markers was
demonstrated in Southeast Asia where *P. falciparum* resistance against artemisinin (ART) was associated
with mutations in the Kelch protein 13 (*K13*) (9-12), and resistance mutations in this same gene recently
emerged in Africa (13).

In addition, monitoring population genetic markers can guide control and elimination strategies by
identifying drug resistance gene flow, distinguishing imported from autochthonous cases and estimating
the source of reintroduced cases in malaria-free areas (2, 14-16). Parasite genetics can identify
underlying patterns of transmission and transmission intensity (17).

The gene products of *P. falciparum hrp2* and *hrp3* are detected by rapid diagnostic tests (RDTs), and
gene deletions resulting in false-negative RDT results were first detected in Peru 10 years ago (18). Since
then, there have been more reports from many areas (19-22)(23, 24), raising concerns for the viability of
HRP2-based RDTs. The WHO recommends assessing prevalence of *hrp2* and *hrp3* mutants among
malaria patients and to change case-management strategies when more than 5% of infections contain
deletions (25).

Different genetic markers are required to address the forementioned challenges, and are most
efficiently targeted in a single genomic tool (3, 26). Whole genome sequencing (WGS) can provide the
highest information content per sample, however, implementing WGS for surveillance is constrained by
the limited access to high-throughput sequencers and lack of technical and bioinformatic skills in
endemic countries. As a result, sequencing is often performed through genomic consortia, delaying the
turn-around-time from sample collection to genetic data, and limiting its usefulness to NMCPs. In
addition, obtaining high-quality WGS data from low density infections and dried blood spots (DBS)
remains challenging. Consequently, it is rare for genomic surveillance to be used beyond research (27-
29).

Targeted Next Generation Sequencing (NGS) tools are emerging that combine numerous targets of
interest into one workflow and more time and cost-efficient than WGS or traditional PCR-based
approaches with amplicons detected by different techniques (10, 30-33). Laboratory protocols for NGS-
assays are well-standardized, sequencing is feasible on benchtop sequencers and automated analysis
pipelines are available (2, 6), for example the MaRS assay (34) that targets multiple drug resistance
markers. While microsatellites have frequently been used for population genetic surveillance as they are
not under evolutionary pressure, these markers are not easily translated to NGS due to the short
repetitive nature of the variation. Instead, SNP barcodes can be successfully targeted by NGS (35-37),
are informative for connectivity between populations (38, 39) and prediction of infection origin (40, 41).
The SpotMalaria platform combining drug resistance markers with a SNP barcode was helpful in tracking
the rapid spread of resistant parasites in the Greater Mekong Subregion (42).

Currently, there is no multifunctional tool suitable for more than two 'use cases'. The characterization of
hrp2 and *hrp3* deletions still relies on PCR assays that classify deletions based on failure to amplify
targets (23). The few existing tools that combine population markers with drug resistance target short
regions around validated resistance SNPs, missing the potential to detect novel resistance associated
mutations. Furthermore, many SNP-panels were designed from genomes across the world and lack the
resolution to study subtle patterns on a smaller geographical scale. Therefore, we designed a targeted
NGS-assay (Pf AmpliSeq) that combines a specifically designed barcode for the target country, 13 full
length resistance associated genes, *hrp2* and *hrp3*, and a *ama1* microhaplotype region. The assay is
applicable to DBS and adaptable to different settings. The AmpliSeq technology (43) applies a multiplex
PCR to simultaneously amplify a high number of targets in a rapid procedure, and allows overlapping
amplicons to cover large genes.

We applied the Pf AmpliSeq assay to Peruvian samples for assay validation. *P. falciparum* in Peru makes
a good case-study, as malaria elimination is on the regional agenda (44), with countries first targeting *P.*
falciparum elimination due to its lower case load than *Plasmodium vivax*, but also in fear of emerging
ART-resistance. South America has been a hotspot for chloroquine (CQ) and sulphadoxine-
pyrimethamine (SP) resistance evolution (45). More recently, *K13*-mediated ART-resistance emerged in
Guyana (46, 47), and *K13*-independent delayed parasite clearance after ART-treatment was reported in
Suriname (46, 48, 49). *P. falciparum* elimination is also threatened by the increasing prevalence and
spread of *hrp2* and *hrp3* deletions (21, 23).

Peru reduced malaria case incidence by ≥40% in 2010 (Figure 1), and, after a resurgence in 2016, cases
have been decreasing in the past 5 years after introduction of focal screening and treatment (50). Past
high levels of CQ and SP-resistance (51-54) led to Peru becoming one of the first countries in the
Americas introducing artemisinin combination therapy (ACT) in 2001 (54-56). However, ACT efficacy and
drug-resistant markers have not been monitored in Peru since 2009. In 1998-2001 up to 20% of
infections in Peru were *hrp2* deleted, increasing to 53% *hrp2* deletions and 37% deletions of both genes
in 2012-2014 (18, 19). In this study, we demonstrate the added value of molecular surveillance in Peru
with different 'use cases' using our Pf AmpliSeq assay and explore the changes of the parasite
population in the past two decades.

Figure 1 – Annual *P. falciparum* cases in Peru (black line) from 1992-2020, with first-line treatment policy changes
(source of data: Centro Nacional de Epidemiología, Prevención y Control de Enfermedades (2020) Sistema de
Atención de Solicitudes de Acceso a la Información Pública Vía internet del Ministerio de Salud. Available at:
http://www.minsa.gob.pe/portada/transparencia/solicitud/). Artemisinin combination therapies were first
introduced in the Amazon region in Peru in 2001, contributing to a dramatic decline in cases. Artesunate
mefloquine with primaquine (AS + MQ +PQ) has always been the recommended first-line treatment in the Amazon
region (51) with continued high efficacy (57), and AS+SP was used on the North Coast. In 2015, AS+MQ+PQ
became the recommended first-line treatment in the whole country (58). Peru reduced malaria case incidence by
≥40% by 2010 using passive case detection (PCD), diagnosis with light microscopy and treatment with AS+MQ as
main components of the control program (59). In 2015, with the realization that PCD missed asymptomatic
infections (60), focal screening and treatment was introduced, resulting in a further reduction of malaria incidence
(50). CQ + PQ = chloroquine + primaquine; SP = sulfadoxine-pyrimethamine; QN = quinine.

Results

Pf AmpliSeq design and performance
A panel of 13 *P. falciparum* drug resistant associated genes (Table 1) and corresponding variants of
interest, *i.e.* (putative) resistance associated mutations (Supplementary file 1), were included in the
assay design. The selected genes included validated mutations (4, 7) or variants relevant for Peru, *i.e.*
previously reported or associated with historically- and currently-used drugs. Additional targets were:
hrp2 and *hrp3* genes, the apical membrane antigen 1 (*ama1*), conserved *Plasmodium* membrane protein
(*cpmp*) (61) and microsatellites (MS) *poly-alpha, ARAII, TA81* and *PfPK2* (62). We designed a barcode of
28 SNPs with in-country resolution in Peru (Supplementary file 3). The final assay included >85% of
desired regions in 233 amplicons (Supplementary file 2) with varying amplicon length (55-323 bp). The
cpmp region and a small section of the *crt* gene failed in the primer design, including *crt* variant I218F.

We validated the assay with *P. falciparum* cases (n=312, Figure 2) from multiple previous studies in Peru,
laboratory strains (n=5), and previously genotyped isolates (n=6) as controls. A high number of reads
was generated in the assay (mean 217,037 ± 490,478 paired reads/sample after trimming low quality
reads) with a median of 99.6% [range 3.9-99.9%] of trimmed reads aligning to the Pf3D7 genome.

Targets regions were covered with a mean 1,336±3,627 paired reads (range 20-43,795). To improve
nucleotide diversity in the run (30% GC content), we tested a 20% spike-in of PhiX-library, however, this
is not recommended as it did not result in a more high-quality reads (9.7%±10.6 poor quality reads were
trimmed without spike-in *vs.* 10.3%±7.3 with spike-in), and reduced total read number.

159
Figure 2 – Map of study sites of retrospective sample collection from the Peruvian Amazon region Loreto (grey).
The majority of samples were collected in Maynas Province (areas 1, 2, and 3): samples collected in/near the San
Juan Bautista district (area 3), which covers part of the urban area of Loreto's capital Iquitos and peri-urban
communities south of Iquitos (n=226), and samples from the Mazán district (area 1; n =17) and Punchana district
(area 2; n =64) with remote communities living near forest rivers such as the Amazon River and Napo River, North
of Iquitos. A final collection of samples from 2018 was available from the Northern Amazon region in Datem del
Marañón Province, Pastaza District (area 4, n=5). *P. falciparum* positive samples from previous studies were
selected based on geographical representation and parasite density (≥100 p/µl by PCR; geometric mean density
4300±3.1 p/µl).

Depth of coverage
Median amplicon depth of coverage of aligned high quality reads past filter (DP) was 82.9 [IQR 42.9-
116.1] (Figure S1). Fifteen (6.4%) amplicons had poor DP (<10; Table S1), while six (2.6%) had high DP
(>150; Table S2). Among those, four *hrp2* and *hrp3*-amplicons had lower DP in the study samples, but
not in controls, due to high prevalence of deletions in these genes. Lower DP in other amplicons is likely
due to sequence variation in primer binding sites, resulting in poor amplification and high amount of
missing data in these regions, *e.g.* A220S in *crt*. In contrast, two *hrp2*-amplicons had much higher depth
than average, possibly due to cross-alignment between *hrp2* and *hrp3* repetitive regions. In 23/233
amplicons no variants (*i.e.* only reference alleles) were detected despite good amplification and
sequencing (Table S3), and these amplicons were in conserved regions of drug resistance genes.

Uninfected controls

Primer specificity was tested with four uninfected human blood samples (negative controls), and none of these resulted in genotypes in the assay target region. We did observe background sequences, with a very low number of reads corresponding to multiple unspecific hits to Plasmodium and human sequences; all of them outside the assay target regions and below the filtering threshold.

Eight stored previous library preparations (incl. control samples and one human negative) were included to test replicability, but this resulted in a contamination in the human negative. In the initial run this control was not contaminated, and none of the new library preparations were contaminated with these specific genotypes.

Parasite density limit and selective whole genome amplification

DP decreased while missingness increased with decreasing parasite density in a dilution of 3D7 (6000 to 6 parasites/µl (p/µl)) at a DNA concentration mimicking dried blood spots (DBS). At the lowest density (6 p/µl), DP was only 10, and 60% of loci were missing. Selective whole genome amplification (sWGA) prior to library preparation improved the number of high quality reads at parasite densities below 60 p/µl (Figure S2); with 10-fold more reads at 60 p/µl to 90-fold at 6 p/µl.

Error-rate and reproducibility

Sequencing accuracy was higher in biallelic SNPs (mean error-rate 0.008%±0.004) compared to indels (0.02%±0.005) (Table S4). At parasite densities >6 p/µl, sWGA is not recommended, as error-rates were higher with sWGA (0.13% ± 0.06) than without (0.05% ± 0.01), with little gain in coverage.

The reproducibility of the assay was tested, with a median difference of 4 SNPs (0.6% of SNP loci; 0.007% of 57445bp targeted in the assay) between sample and control replicates observed. With indels and multiallelic variants, a median difference of 50 alleles (2.8% of loci; 0.09% of 57445bp) was observed.

In comparison to previous results with laboratory strains and control samples, 97.6% of genotypes were accurate (Table S5). In the control samples, 7.9% additional heterozygous genotypes were detected by AmpliSeq, which might have been previously undetected minor clones due to lower sequencing depth in the SpotMalaria pipeline and WGS data.

Complexity of Infection

Minority clones could be detected in the Pf AmpliSeq assay up to a 80:20 of 3D7:Dd2 mixture with 43.8% (28/64) Dd2-loci detected (Table S6). Below 95:5 few Dd2-genotypes were detected.

The complexity of infection (COI) estimates the number of genetically distinct clones in an infection, which can be used as a proxy for transmission intensity (16, 63). We applied different methods to determine COI from NGS, but results varied considerably by method (Table S7). Therefore, we determined the most frequent value (mode) of COI, which showed an increasing proportion of multiple clone infections in Peru over time (13.8% in 2003-2005; 28.8% in 2008-2012; 33.3% in 2014-2018; X^2 p=0.0005) (Figure S3).

Use case *hrp2* and *hrp3* gene deletions

Compared to prior PCR-classification, all samples (10/10) were correctly classified for 'RDT-failure'
(deletion of both genes) *vs.* 'RDT-detectable' (presence of one or both genes) using the read depth of
hrp2 and *hrp3* amplicons. For 6/10 samples, classification was correct for both genes, but in 4 four
samples the *hrp2*-classification was inconclusive (Table S8), due to discrepancy in classification between
amplicons.

With the Pf AmpliSeq assay, 94.9% (241/254) of study samples could be classified as 'RDT-failure' or
'RDT-detectable'. The proportion of individuals with 'RDT-failure' increased from 17.7% in 2003-2005 to
42.6% in 2008-2012 and 73.3% in 2014-2018 (X^2, p>0.001). While *hrp3* presence *vs.* absence could be
determined for most samples (96.5%), 26.8% of *hrp3*+ samples were inconclusive for *hrp2* (Figure S9),
but since they were not *hrp3* deleted, were classified as 'RDT-detectable'.

Barcode performance

227   All 28 barcode SNPs were detected in the assay (Table S9), although one (Pf3D7_12_1127001) was
228   genotyped as an indel. In the study samples, population minor allele frequencies (MAF) of the barcode
229   SNPs ranged between 0.35-0.50 at 9 loci, between 0.1-0.34 at 12 loci and <0.1 at 7 loci. We did not
230   observe the minor allele of one of the barcode SNPs (Pf3D7_05_921893) in the study samples, although
231   it was detected in laboratory strains (n=5), and 5/6 control samples.

Use case transmission intensity: Genetic diversity & differentiation

Principal component analysis (PCA) showed sample clustering by year rather than collection site (Figure
S4), therefore the samples were divided in three time periods for subsequent analyses: 1) early time
period (2003-2005), 2) intermediate time period (2008-2012), and 3) most recent period (2014-2018)
where little variability was observed.

Genetic diversity (expected heterozygosity, *He*) of the parasite population, was lower in 2008-2012
(p=0.003) and 2014-2018 (p=0.00004) than in 2003-2005 (Figure 3A). Total population size was small, as
the observed heterozygosity (*Hobs*) was lower than *He* (p<0.005), indicating that genetic diversity was
lower than expected from a population in Hardy-Weinberg equilibrium. The parasites in 2008-2012 and
2014-2018 showed great genetic differentiation (F_{ST}>0.25) compared to parasites in 2003-2005 (Figure
3B). The parasite population changed considerably since 2008, with a less diverse and smaller
population.

Figure 3 - Population genetic statistics. A) Genetic diversity (expected heterozygosity, *He*) for each barcode locus (black dots) grouped by time-period. Boxplots show a decrease in the median [interquartile range] of *He* after the first time period (2003-2005). Since differences in He might be due to unequal sampling in districts through time, we assessed He within San Juan Bautista district that was sampled at all three time-periods. This confirmed decreasing diversity over time, with a pronounced decrease in He in 2014-2018 (p >0.001, Figure S5 and table S10). **B)** Genetic differentiation between the three populations measured as F_{ST} (Weir & Cockerham, 1984) using the R package diveRsity. Number of individuals for each population: $n_{2003-2005}$ = 118; $n_{2008-2012}$ = 65; $n_{2014-2018}$ = 38. In Figure S5 *He* by time and district is plotted and in Figure S6 the differentiation measures $G`_{ST}$ (Hedrick, 2005) and Jost's D (Jost 2008) are plotted.

Use case connectivity of parasite populations: Barcode multilocus lineages and population structure

We identified 36 multilocus (ML) lineages with distinct barcodes in the study population over time (Figure 4) and districts (Table 2). The distinct lineages clarify the significant linkage disequilibrium (LD) in the barcode in all time periods and districts (Table S11). In 2003-2005 we observed 23 lineages, and only 11 in 2008-2012, matching the decrease in *He*.

Lineage no. 155 became predominant after 2008, with many related lineages (Figure S7), explaining the small population size and increasing number of barcode alleles that become fixed (2 in 2003-2005; 8 in 2008-2012; 14 in 2014-2018; Table S12). The predominant lineage was in in co-existence with others within district and period. The ML-lineages in later periods (2008-2018) changed considerably since 2003-2005 paralleling observed F_{ST}.

Figure 4 - Dynamics of 28-SNP barcode multilocus lineages. Area plot showing the proportions of each ML-lineage

detected in the three different time periods in study samples (n=254) from Peru. ML-lineages were identified,

clustered using genetic distance between barcodes with the poppr package in R, and given an identifying number.

ML-lineages differed by multiple SNPs (≥4 SNPs), enabling lineage classification even when barcodes had some

missing or heterozygous genotypes. Lineages are characterized by unique barcodes and resistance genotypes and

listed in table 2.

With discriminant analysis of principal components (DAPC), the resolution increased to all biallelic

variants (n_{loci}=772), and we determined the underlying causes of the population differentiation (Figure

5). The highest contributing alleles along the first axis (2003-2005 *vs.* 2008-2018) were drug-resistance

mutations *dhfr* C50R and N51I, *mdr1* D1246Y, and *dhps* K540E (Table S13). Contributors to the

differentiation along the second axis (2014-2018 and Pastaza) were seven barcode SNPs and *dhfr*, *mdr1*,

coronin and *ubp1*-variants.

Figure 5 - Discriminant analysis of principal components (DAPC). Scatter plot of discriminant analysis (DA) eigenvalues 1 and 2 using all biallelic SNPs in the core targeted region (excl. amplicons targeting repetitive regions and non-nuclear targets), showing a differentiation between Peruvian *P. falciparum* samples collected before 2008 and those afterwards (x-axis, PC1), and a subsequent separation along the y-axis (PC2) from 2014 to more recent years and along geographic distance. SNPs contributing most to the DAPC are listed in Table S13. DAPC was performed with 40 principal components and 7 discriminants as determined through cross-validation. The increased resolution in the DAPC allowed the detection of greater genetic variation in isolates from 2014-2018 (black shapes), compared to lineage analysis.

Use case drug resistance: Artemisinin resistance-associated genes

The full-length *K13* gene was amplified with 12 overlapping amplicons. We detected several ART-resistance validated SNPs in control samples, but did not observe these SNPs (F446I, N458Y, M476I, Y493H, R539T, I543T, P553L, R561H, P574L and C580Y) in the study samples. We observed several low frequency mutations in the K13-propellor region (V445A, I448K, G449C, V581I, premature stop codon at 613; Table 3), always in mixed infections. Outside the propeller region, the K189T mutation was observed at a high frequency (63%-84%).

Forty-four amplicons covered the *ubp1* gene (91.8% of the gene), including all variants of interest. Previously reported variants (incl. R3138H) were not detected, but we observed a change in the predominant *ubp1*-haplotype. In 2003-2005, a haplotype with Q107L, commonly with K1193T, was most frequently observed (42.6%; Table 3). In later years, R1133S-haplotypes (often linked with E1011K) replaced the Q107L-haplotypes.

Eleven amplicons amplified full-length *coronin* gene. We identified two novel mutations V62M and V424I, and none of the *in vitro* associated variants. V62M was seen at 20.6% in 2003-2005, but decreased over time (Table 3). V424I increased from 55.4% in 2003-2005 to 80.9% in 2014-2018 (Table

301 3). While V62M is located in the WD-40 beta-propeller domain (containing validated mutations G50E,
302 R100K and E107V), V424I is located just outside this region and is not expected to contribute to ACT
303 resistance.

Use case drug resistance: CQ and ACT partner drug resistance associated genes

304
The SP-resistance associated genes were each targeted with 9 amplicons, covering 100% of *dfhr* and
87% of *dhps*, incl. all variants of interest. In 2003-2005 we observed predominantly single (69.5%) and
double (22.7%) *dhfr* mutants, and wildtype (*wt*) *dhps* (≥56.7%; Table 3). Although SP-use was
discontinued in 1999, after 2008, SP-resistance increased with high frequency of triple mutants in *dhfr*
and *dhps*. Consistent with previous reports (45, 64), we did not detect *dhfr* C59R in Peru. Therefore, the
'sextuple' mutant here is different from the African sextuple mutant, with C59R instead of C50R, but
similar super resistant phenotype (65).

Sixteen amplicons covered the *crt* gene (91.1%), missing one variant of interest (I218F) associated with
PPQ resistance. CQ resistance (CQR) *crt* haplotypes, CVMNT (CQR) and SVMNT (highly CQR), increased
over time (Table 3) with 100% SVMNT in 2014-2018. The mutation I356V, whose contribution to CQR is
unclear, was frequent (>93%) in all time periods.

Eighteen amplicons covered the *mdr1* gene (87%), targeting all variants of interest associated with CQ
and MQ-resistance (7). While the *mdr1* haplotypes NDFCDD and NGFSDD were predominant in 2003-
2005, in later years it was mainly the NDFCDY haplotype (Table 3). There are conflicting results on the
association of NDFCDY with susceptibility to MQ, AS and CQ (64, 66). The *mdr1* D144G SNP has so far
only been reported in Peru (annotated as D142G in (64)) and is decreasing in recent years.

Copy number variations (CNVs) in *mdr1* and *plasmepsin II* associated respectively with PPQ (67) and MQ
(68) resistance were not previously observed in Peru (69). We confirmed single copies of both genes by
qPCR in a subset of 78 samples (Figure S8). While both genes were sequenced in our assay, the lack of
increased copy numbers resulted in insufficient data to validate CNV detection by Pf AmpliSeq.

We did not detect many variants of interest in the other targeted genes, with 10.6% of the S160N
mutant in 2003-2005 in the *ap2-mu* gene (9 amplicons covering 99.1% of the gene), which decreased in
later periods (1.5% and 2.2%). No variants of interest were observed in *pfmrp1* (95.1% covered),
pfexonuclease (98.6% covered), *cytochrome B* (100% covered) and *23S rRNA* gene (100% covered).

Use case drug resistance gene flow: drug resistance and parasite lineage evolution

329
Between 2003 and 2005, we observed lineages with predominantly single and double *dhfr* mutants, *wt*
dhps, CVMNT and SVMNT *crt*-haplotypes, multiple *mdr1*-haplotypes and presence of *hrp2* and *hrp3*
deletions (Table 2). From 2008, the majority of parasite lineages harbored sextuple *dhfr/dhps* mutants,
crt SVMNT, *mdr1* NDFCDY, and *hrp2* and/or *hrp3*-deletions. Parasites with this *dhps/dhfr/crt/mdr1*
resistance haplotype and both *hrp2* and *hrp3* deleted were first reported in few cases from Peru in 2006
(64) and called the B_{V1}-lineage. Here, we observed many parasites with the same 'B_{V1}-type' resistance
haplotype, although not always with *hrp2* and *hrp3*-deletions. With the greater resolution in the Pf
AmpliSeq assay, we observed many related lineages with this resistant haplotype that differ in the
barcode genotype, presence of *hrp2* and *hrp3*-deletions, and *coronin* SNPs (Table 2). This indicates gene
exchange between lineages contrasting the idea of isolated clonal lineages in Peru.

The B$_{V1}$-type lineages are closest related to earlier lineages 158, 141 and 63 in our study samples (Figure
S7), but the triple *dhfr* mutants are not accompanied by the secondary mutations (I164L and the
"Bolivian Repeat" (BR), a silent 5 amino acid insertion before codon 30), indicating that they did not
emerge from the double *dhfr* lineages circulating in earlier years. In conclusion, the combination of
different markers in the Pf AmpliSeq assay allowed the identification of multiple recombining *P.*
falciparum lineages in Peru that share increasing SP and CQ resistance, as well as RDT failure, in more
recent years.

Discussion

We designed a new highly-multiplexed sequencing assay (Pf AmpliSeq) targeting 13 antimalarial
resistance genes, combined with a country-specific 28-SNP barcode for population genetic analysis in
Peru and *hrp2* and *hrp3* genes to detect deletions that can cause false-negative RDT results. The novelty
and strength of this assay is in the many different types of markers multiplexed in one easy workflow,
making it suitable for many surveillance 'use cases'. Compared to other amplicon sequencing assays (30,
34, 70) and genetic surveillance platforms (71), the Pf AmpliSeq includes the highest number of drug
resistance associated genes, combined with an in-country SNP-barcode, as well as diagnostics resistance
markers.

This assay performs well on DBS samples with parasite densities ≥60 p/μl, and allows for high accuracy
sequencing at higher depth of coverage (100-1000 fold *vs*. 50-100 fold) and lower cost (Table S14) than
WGS. At densities <60 p/μl, sWGA prior to the Pf AmpliSeq assay increases the number of reads, but also
the error rate and cost. Initial raw data processing can be performed automatically using software of the
sequencer, with no need for linux-based pipelines as we have used (giving us more flexibility and insight
during the validation). Subsequent variant analysis can be performed on a regular computer with
minimal bioinformatic skills using any software that can analyze tabulated data.

While the assay was capable at detecting ART-resistance validated SNPs in *K13,* only non-validated SNPs
were detected at low frequency in the Peruvian samples used for assay validation. Without presence of
validated markers in *K13*, there is no evidence suggesting the emergence of ART resistance in Peru in
recent years (2003-2018). Mutations in other genes in the endocytosis pathway have been associated
with decreased sensitivity to ART in *in vitro* studies and changes in *ubp1*-haplotypes paralleled the
emergence of *K13* markers in Thailand (72-81). However, the observed *ubp1* and *coronin* mutations here
are uncharacterized. Genetic variants in KIC7, Eps15, Formin2 associated with *in vitro* ART resistance
(74-76, 78, 82) were not reported yet when the assay design was being completed. These genes will be
included in future versions of the assay.

This is the first proof-of-principle of an NGS-amplicon assay targeting *hrp2* and *hrp3*-deletions, detecting
56.3% samples with both *hrp2* and *hrp3* deleted. This might be an underestimation, since infections
containing mixed strains with and without deletions might be classified as 'RDT-detectable'. It was
difficult to classify *hrp2* for 22% of samples, due to conflicting results between *hrp2* amplicons. The
difference in read depth with different *hrp2* amplicons suggests that potentially only a part of the gene
is deleted, with (part of) the first exon still present. Better characterization of the genomic structure of

hrp2-deletions could improve amplicon design. In addition, copy number calling tools could be explored
for more systematic classification of *hrp2* and *hrp3*-deletions.

With the combination of phenotypic markers and the 28-SNP-barcode in the Pf AmpliSeq assay, we were
able to detect changing allele frequencies in resistance associated genes, but also to identify temporal
genetic differentiation in the parasite population, alongside a decrease in genetic diversity. The barcode
served to distinguish different lineages in multiple resistant (*dhfr/dhps/crt/mdr1*) haplotypes circulating
in recent years, and enabled the investigation of drug resistance evolution.

SP- and CQ-resistance in South America was reportedly spread from a single origin in the lower Amazon
(45), with five distinct clonal lineages circulating in Peru before 2006 (19, 64, 83), followed by frequent
outcrossing and lineage evolution (83). With the Pf AmpliSeq, we observe the same SP/CQ-resistant
lineages and their evolution over time, with increased resolution and additional variants detected in
other genes.

The BV$_1$-type lineages that increasingly dominate the Peruvian parasite population after 2008, are highly
SP/CQ-resistant, and can frequently escape HRP2-based RDTs. The Pf AmpliSeq assay could characterize
outbreaks, such as the BV$_1$-outbreaks in Tumbes (84) and Cusco (85). What pressure selected the BV$_1$-
type lineages is unclear, as there is no clear evidence of ART-MQ resistance (absence of *K13*-variants and
mdr1 CNV) and HRP2-based RDTs are not commonly used in Peru. The high level of CQR (in *crt* and
mdr1) could be the result of CQ-treatment of co-endemic *P. vivax* cases. Co-infections are frequent (86),
and can occur with low density *P. falciparum*, and frequently misdiagnosed and treated as *P. vivax*
mono-infection (83). When the BV$_1$-type lineages first appear (2011), we observed strong population
differentiation and loss of secondary *dhfr* mutations, which supports the suggestions from others that
this lineage was introduced from other parts of the Amazon (84, 87), possibly Colombia (20, 21) or
Suriname (49). Analysis of isolates from neighboring countries could shed light on the evolution and
spread of resistance and *hrp2* and *hrp3* deletions in the region. Predicting the origin of imported
infections based on SNPs is possible (40, 41, 88), however, samples from neighboring countries were not
available to investigate the spatial dynamics within this study. Existing public WGS datasets lack isolates
from sufficient countries in South America for a comprehensive analysis.

Ideally, to update genomic regions of interest, periodic WGS of a subset of samples should be performed
to investigate the emergence of mutations not targeted by the Pf AmpliSeq assay. Newly identified
regions could be added to the design. Similarly, we can exchange the SNP-barcode for application in
different countries, resulting in a modular design adaptable to the needs of a particular setting. The
assay in its current form is limited to South America. However, we are validating Pf AmpliSeq assays for
South East Asia and Sub-Saharan Africa, including also other ART-resistance genes, and *P. vivax* Ampliseq
assays.

Conflicting COI results were obtained due to differences between methods. In addition, the variant
calling tool used here assumes a diploid genotype with balanced within-sample allele frequency, which
is frequently not the case in malaria complex infections. Alternative haplotype-based analysis
approaches are available (*e.g.* SeekDeep (89), HaplotypR (61), and DADA2 (90)) that might have a
greater capability at unraveling complex infections, and more suitable for relatedness analysis (*e.g.*

identity-by-descent (91)). These methods could work with the existing design, or by adding
microhaplotypes (70). However, they are less easy to use for drug resistant markers and overlapping
amplicons.

As half of the barcode SNPs became fixed in the most recent years, the usefulness of the barcode in
future years might be limited. This likely reflects a true decrease in diversity as the sample size was
sufficient, and there are closely related clonal lineages. The sample size in this study was comparable to
earlier reports from Peru (*e.g.* 220 samples in 1999 (83), 104 samples from 1999 and 62 from 2006-2007
(64)), but represents a limited proportion of the Peruvian *P. falciparum* population. A more systematic
sampling approach of dried blood spots at many more sites within the country would be ideal for
routine genetic surveillance.

Concluding remarks
This study described a *P. falciparum* population in Peru with increasing accumulation of drug and
diagnostic resistance and spread of these lineages can be a serious threat to *P. falciparum* elimination
throughout the Amazon region. This study highlights the importance of systematic resistance monitoring
in the country, which is currently lacking, and offers a surveillance tool for multiple genetic 'use cases'.
Implementation will require a structured approach that will most importantly not unnecessarily burden
existing health systems and is sustainable for the long term. A molecular surveillance network (GENMAL)
has been established to stimulate wide-scale implementation and standardization of markers for
surveillance. This network will be a platform for coordination of research in Peru, data sharing and
efficient translation of results into policy-advice and practical guidelines for malaria elimination in Peru.
The type of multiplex assay as presented here could be more broadly applicable for the wider Amazon
area and South America to fill the void of genetic data from this region.

Materials and methods

Study sites, samples and controls
P. falciparum positive samples (n=312) from previous studies were selected based on geographical
representation (Figure 2) and parasite density (≥100 p/µl by PCR). Samples from 2003-2017 (n=269)
were from studies led by Universidad Peruana Cayetano Heredia (UPCH) ((18, 92) and ongoing), and the
U.S. Naval Medical Research Unit 6 (NAMRU-6) (n=63). Samples from 2018 (n=5) were the only *P.*
falciparum positive samples from a Zero Malaria Programme collection in Loreto in collaboration with
UPCH.

DNA was extracted from DBS using the E.Z.N.A Blood DNA Mini Kit (Omega Bio-tek, Georgia, USA)
following instructions. Per sample, two pieces of ~0.5 cm^2 were cut out and 100µL DNA was eluted. *P.*
falciparum parasitaemia was qPCR quantified (93).

The studies were approved by local ethical review boards. Protocols were registered in the
Decentralized System of Information and Follow-up to Research (SIDISI) (numbers: 52707, 61703,
101645, 66235, 102725), and one clinical trial registered at clinicaltrials.gov (NCT00373607). The
NAMRU-6 study was approved by its Institutional Review Board in compliance with all applicable federal
regulations governing the protection of human subjects (protocol NMRCD.2007.0004). Individuals were

included in this study only if signed informed consent included a future-use clause, and secondary-use
was approved through the Institutional Review Board of the Institute of Tropical Medicine Antwerp
(reference 1417/20).

For the final analysis we selected 254/312 (81%) samples with good quality data (<50% missing
genotype calls, mean coverage >15) and retaining only one library of replicates (with lowest
missingness). With a sample size of 96 samples a MAF of 0.01 with 0.02 (2%) precision could be
detected, and with 381 samples MAF=0.01 with (1%) precision
(https://epitools.ausvet.com.au/oneproportion).

Laboratory isolates and uninfected human blood were included as controls (Table S15). Control samples
(n=6) with known variants from a previous study in Vietnam (94) genotyped with the SpotMalaria
pipeline and WGS were also included. DNA of controls (100µL) was extracted using QIAamp DNA Mini
Kit (Qiagen) following instructions. sWGA was performed as previously described (95). Genotypes of the
laboratory strains were from (69, 96-98).

SNP-barcode design
A barcode of 28 biallelic SNPs was designed (Supplementary file 3). Briefly, MalariaGEN *Plasmodium*
falciparum Community Project data (99) was used to select SNPs (0.35≤MAF≤0.5) contributing to
between-country differentiation using DAPC (100). Two SNPs per chromosome were selected with
priority for synonymous SNPs with low pairwise-LD.

Pf AmpliSeq workflow and sequencing
Library preparation was performed using AmpliSeq Library PLUS for Illumina kit (Illumina), AmpliSeq
Custom Panels (Supplementary file 2) and AmpliSeq CD Indexes (Illumina) as per the manufacturer's
instructions. DNA concentration for controls and 25 samples was determined using Qubit v3 High
sensitivity DNA kit (Invitrogen) and controls were diluted to 1 ng input DNA to mimic DBS samples. Study
samples (mean DNA concentration 6.1±0.3 ng/µl) were not diluted. Target regions were amplified with
adjusted cycling conditions (1x99°C-2min; 21x99°C-15sec; 1x60°C-8 min) in two reactions, and
subsequently combined for final library preparation according to the guidelines. Libraries were
quantified using KAPA Library Quantification Kit for Illumina Platforms (KAPA Biosystems), diluted to
2nM with low Tris-EDTA buffer, and pooled. Denatured library pool (18pM) was loaded on a Miseq
system (Illumina) for 2x300 paired-end sequencing (Miseq Reagent Kit v3, Illumina). A detailed protocol
is available at bio-protocol.org/###. 20% PhiX spike-in (Illumina) was used in one sequencing run to
determine the effect on sequencing quality and trade-off in coverage. Generated demultiplexed FASTQ
files were processed with an in-house analysis pipeline on a Unix operating system computer
(Supplementary file 3).

Detection of *mdr1* and *pm2* copy number variations by PCR
CNVs in *pm2* and *mdr1* were determined in a subset of samples (n=78) from all time periods and
districts using qPCR (94). Samples and controls were tested in triplicate with 20% of samples re-tested
for reproducibility with 100% of results in agreement.

Analysis of Complexity of infection

COI was estimated using the Real McCOIL categorical and proportional methods (101) in R using subsets
of variants: 1) all biallelic SNPs, 2) 25 barcode SNPs, 3) "core variants": biallelic variants excluding
repetitive regions (*i.e. hrp2*, *hrp3* and MS) and mitochondrial and apicoplast regions. Default settings
were used for a fixed error, and for the categorical method an upper bound of 10, and initial COI of 5
and for the proportional method an upper bound of 15, and initial COI of 7. We allowed 50%
missingness for biallelic SNPs, 20% for the barcode and 40% for core variants.

We also estimated the proportions of single and multiple clone infections based on the number of
heterozygous genotypes in 1) the 28-SNP barcode, 2) biallelic SNPs in *ama1*, and 3) core variants.
Samples with ≥1 heterozygous genotype were considered to contain multiple clones (COI≥2). Finally, we
estimated COI from the MS amplified regions. As the different methods generated diverging results, the
mode (most frequent value of single *vs.* multiple clone) was determined as final measure for each
sample.

Validation of detection of *hrp2* and *hrp3* deletions
The Pf AmpliSeq performance for *hrp2* and *hrp3* deletion detection was assessed in 10 previously-typed
samples (31). The presence or absence of both genes was determined using the mean read depth of
hrp2 and *hrp3* amplicons (Supplementary file 3). Due to the repetitive nature and homologies between
hrp2 and *hrp3* genes we used a conservative cut-off value, resulting in a "grey zone" where
deletion/presence was left inconclusive when the majority of amplicons were not in accordance. A final
variable for 'RDT-failure' (both *hrp2* and *hrp3* absent) *vs.* 'RDT-detectable' (*hrp2* and/or *hrp3* present)
was created, allowing the classification of samples that were inconclusive in one of the two genes if the
other gene was present.

Population genetic analysis
Population genetic analyses were performed using the 28-SNP barcode, excluding samples missing >7
SNPs (25%). Samples with heterozygous genotypes were included, justified by little genetic
differentiation (F_{ST}=0.05) between samples with single clone barcodes *vs.* samples with heterozygous
barcode genotypes. Genetic differentiation was measured as F_{ST} (102), G`$_{ST}$ (103) and Jost's D (104) using
1000 bootstraps with the R package DiveRsity (105). PCA was performed on the genotype matrix using
'prcomp' function (R stats package v4.0.5) using core variants. Prior to PCA, missing genotypes were
replaced by the mean allelic frequency at a locus in all samples. Expected heterozygosity (*He*) was
calculated (adegenet package (106, 107) in R) using diploid barcode genotypes. Wilcoxon signed-rank
test with continuity correction was used to compare mean observed heterozygosity (*Hobs)* to *He*. LD
was measured as the standardized index of association ($\bar{r}D$) in multilocus analysis using 999 resamplings
(method: permutation of alleles) using the poppr package v2.8.6. (108) in R. ML-lineages were defined
by grouping isolates with similar barcodes using the Hamming distance and clustered based on the
maximum distance (farthest neighbor) using poppr. DAPC (100) was performed with cross-validation,
and associated allele loadings for the first four components were determined.

Analysis of genetic variants
Barcode allele frequencies were calculated from allele depths to reflect population allele frequencies in
complex infections (Supplementary file 3). Haplotypes were created by combining genotypes of variants

of interest (Supplementary file 1). Frequency tables with confidence intervals were created with the

freqtables R-package.

Data availability:

Sample meta data and drug resistant and *hrp2* and *hrp3* haplotypes, barcodes, lineages location, date, etc. is accessible at https://microreact.org/project/aV7RHNCBmG3sJ2rwzchE4k-peru-2003-2018-molecular-surveillance-with-p-falciparum-ampliseq-assay. Raw data (fastq), variant files (vcf), and scripts are available on request. All other data is included in the manuscript and supporting files.

Acknowledgements:

We wish to thank all clinical, microscopy and field staff who supported the sample collections and all participants for making their material available for malaria studies. We acknowledge the support of the Dirección Regional de Salud de Loreto for the study authorization and sample collection activities in Loreto. The following reagents were obtained through BEI Resources, NIAID, NIH: *P. falciparum*, Strain Dd2, MRA-150, contributed by David Walliker; *P. falciparum*, Strain Dd2_R539T, MRA-1255, and *P. falciparum*, Strain CamWT_C580Y, MRA-1251, contributed by David A. Fidock; and *P. falciparum*, Strain IPC 4912, MRA-1241, contributed by Didier Ménard.

Funding:

This work was funded by the Belgium Development Cooperation (DGD) under the Framework Agreement Program between DGD and ITM (FA4 Peru, 2017-2021) and the sample collections in 2018 were supported by VLIR-UOS (project PE2018TEA470A102; University of Antwerp). Funding for the sample collections lead by the U.S. Naval Medical Research Unit 6 (NAMRU-6) in 2011 and 2012 was provided by the Armed Forces Health Surveillance Division (AFHSD) and its Global Emerging Infections Surveillance and Response (GEIS) Section (P0144_20_N6_01, 2020-2021). Funding agencies had no role in the design of the study.

Competing interests:

The authors declare that they have no competing interests.

Author contributions (in alphabetical order per item): Conception of ideas for the study: ARU, DG, JHK; Selection of targets and design of the assay: ERV, JHK, NvD; Sample collections and coordination of field work: CDG, CFM, DG, HOV, JPvG; Laboratory experiments: CFM, JHK, NvD, PG; Bioinformatics & Data analysis: JHK, LLA, NvD, PM; Writing first draft manuscript: ARU, JHK, CFM, NvD. All authors reviewed and contributed to the final version of the manuscript.

References

1.   WHO. 2019. World Malaria Report 2019. World Health Organization, Geneva.

2.   Committee MPA. 2019. Technical consultation on the role of parasite and anopheline genetics in
malaria surveillance. World Health Organization, Geneva.

3.   Dalmat R, Naughton B, Kwan-Gett TS, Slyker J, Stuckey EM. 2019. Use cases for genetic
epidemiology in malaria elimination. Malaria Journal 18:163.

4.   WHO. 2018. Malaria Surveillance, Monitoring & Evaluation: A Reference Manual. World Health
Organization, Geneva.

5.   WHO. 2009. Methods for surveillance of antimalarial drug efficacy. World Health Organization,
Geneva.

6.   WHO. 2016. Minutes of the Evidence Review Group meeting on the emergence and spread of
multidrug-resistant Plasmodium falciparum lineages in the Greater Mekong subregion. . World
Health Organization, Geneva.

7.   WHO. 2020. Report on antimalarial drug efficacy, resistance and response: 10 years of
surveillance (2010–2019). World Health Organization, Geneva.

8.   Wangdi K, Pasaribu AP, Clements ACA. 2021. Addressing hard-to-reach populations for achieving
malaria elimination in the Asia Pacific Malaria Elimination Network countries. Asia & the Pacific
Policy Studies 8:176-188.

9.   Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, Kim S, Duru V, Bouchier C,
Ma L, Lim P, Leang R, Duong S, Sreng S, Suon S, Chuor CM, Bout DM, Menard S, Rogers WO,
Genton B, Fandeur T, Miotto O, Ringwald P, Le Bras J, Berry A, Barale JC, Fairhurst RM, Benoit-
Vical F, Mercereau-Puijalon O, Menard D. 2014. A molecular marker of artemisinin-resistant
Plasmodium falciparum malaria. Nature 505:50-5.

10. Menard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, Rahim-Awab G, Barnadas
C, Berry A, Boum Y, Bustos MD, Cao J, Chen JH, Collet L, Cui L, Thakur GD, Dieye A, Djalle D,
Dorkenoo MA, Eboumbou-Moukoko CE, Espino FE, Fandeur T, Ferreira-da-Cruz MF, Fola AA,
Fuehrer HP, Hassan AM, Herrera S, Hongvanthong B, Houze S, Ibrahim ML, Jahirul-Karim M,
Jiang L, Kano S, Ali-Khan W, Khanthavong M, Kremsner PG, Lacerda M, Leang R, Leelawong M, Li
M, Lin K, Mazarati JB, Menard S, Morlais I, Muhindo-Mavoko H, Musset L, Na-Bangchang K,
Nambozi M, Niare K, Noedl H, et al. 2016. A Worldwide Map of Plasmodium falciparum K13-
Propeller Polymorphisms. N Engl J Med 374:2453-64.

11. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, Artemisinin Resistance in
Cambodia 1 Study C. 2008. Evidence of artemisinin-resistant malaria in western Cambodia. N
Engl J Med 359:2619-20.

12. Woodrow CJ, White NJ. 2017. The clinical impact of artemisinin resistance in Southeast Asia and
the potential for future spread. FEMS Microbiol Rev 41:34-48.

13. Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana S-I, Yamauchi M, Opio W, Emoto S,
Anywar DA, Kimura E, Palacpac NMQ, Odongo-Aginya EI, Ogwang M, Horii T, Mita T. 2021.
Evidence of Artemisinin-Resistant Malaria in Africa. New England Journal of Medicine 385:1163-
1171.

14. Programme WGM. 2019. WHO Malaria Policy Advisory Committee (MPAC) meeting - meeting
report. Geneva.

15. Mita T, Tanabe K, Kita K. 2009. Spread and evolution of Plasmodium falciparum drug resistance.
Parasitology International 58:201-209.

16. Auburn S, Barry AE. 2017. Dissecting malaria biology and epidemiology using population
genetics and genomics. Int J Parasitol 47:77-85.

17.   Escalante AA, Ferreira MU, Vinetz JM, Volkman SK, Cui L, Gamboa D, Krogstad DJ, Barry AE,
619   Carlton JM, van Eijk AM, Pradhan K, Mueller I, Greenhouse B, Pacheco MA, Vallejo AF, Herrera S,
620   Felger I. 2015. Malaria Molecular Epidemiology: Lessons from the International Centers of
621   Excellence for Malaria Research Network. Am J Trop Med Hyg 93:79-86.
622   18.   Gamboa D, Ho MF, Bendezu J, Torres K, Chiodini PL, Barnwell JW, Incardona S, Perkins M, Bell D,
623   McCarthy J, Cheng Q. 2010. A large proportion of P. falciparum isolates in the Amazon region of
624   Peru lack pfhrp2 and pfhrp3: implications for malaria rapid diagnostic tests. PLoS One 5:e8091.
625   19.   Akinyi S, Hayden T, Gamboa D, Torres K, Bendezu J, Abdallah JF, Griffing SM, Quezada WM,
626   Arrospide N, De Oliveira AM, Lucas C, Magill AJ, Bacon DJ, Barnwell JW, Udhayakumar V. 2013.
627   Multiple genetic origins of histidine-rich protein 2 gene deletion in Plasmodium falciparum
628   parasites from Peru. Sci Rep 3:2797.
629   20.   Murillo Solano C, Akinyi Okoth S, Abdallah JF, Pava Z, Dorado E, Incardona S, Huber CS, Macedo
630   de Oliveira A, Bell D, Udhayakumar V, Barnwell JW. 2015. Deletion of Plasmodium falciparum
631   Histidine-Rich Protein 2 (pfhrp2) and Histidine-Rich Protein 3 (pfhrp3) Genes in Colombian
632   Parasites. PLoS One 10:e0131576.
633   21.   Dorado EJ, Okoth SA, Montenegro LM, Diaz G, Barnwell JW, Udhayakumar V, Murillo Solano C.
634   2016. Genetic Characterisation of Plasmodium falciparum Isolates with Deletion of the pfhrp2
635   and/or pfhrp3 Genes in Colombia: The Amazon Region, a Challenge for Malaria Diagnosis and
636   Control. PLoS One 11:e0163137.
637   22.   Rachid Viana GM, Akinyi Okoth S, Silva-Flannery L, Lima Barbosa DR, Macedo de Oliveira A,
638   Goldman IF, Morton LC, Huber C, Anez A, Dantas Machado RL, Aranha Camargo LM, Costa
639   Negreiros do Valle S, Marins Póvoa M, Udhayakumar V, Barnwell JW. 2017. Histidine-rich
640   protein 2 (pfhrp2) and pfhrp3 gene deletions in Plasmodium falciparum isolates from select sites
641   in Brazil and Bolivia. PLoS One 12:e0171150.
642   23.   Agaba BB, Yeka A, Nsobya S, Arinaitwe E, Nankabirwa J, Opigo J, Mbaka P, Lim CS, Kalyango JN,
643   Karamagi C, Kamya MR. 2019. Systematic review of the status of pfhrp2 and pfhrp3 gene
644   deletion, approaches and methods used for its estimation and reporting in Plasmodium
645   falciparum populations in Africa: review of published studies 2010–2019. Malaria Journal
646   18:355.
647   24.   Thomson R, Parr JB, Cheng Q, Chenet S, Perkins M, Cunningham J. 2020. Prevalence of
648   Plasmodium falciparum lacking histidine-rich proteins 2 and 3: a systematic review. Bulletin of
649   the World Health Organization 98:558-568F.
650   25.   WHO. 2021. Statement by the Malaria Policy Advisory Group on the urgent need to address the
651   high prevalence of pfhrp2/3 gene deletions in the Horn of Africa and beyond.
652   https://www.who.int/news/item/28-05-2021-statement-by-the-malaria-policy-advisory-group-
653   on-the-urgent-need-to-address-the-high-prevalence-of-pfhrp2-3-gene-deletions-in-the-horn-of-
654   africa-and-beyond. Accessed
655   26.   Noviyanti R, Miotto O, Barry A, Marfurt J, Siegel S, Thuy-Nhien N, Quang HH, Anggraeni ND,
656   Laihad F, Liu Y, Sumiwi ME, Trimarsanto H, Coutrier F, Fadila N, Ghanchi N, Johora FT, Puspitasari
657   AM, Tavul L, Trianty L, Utami RAS, Wang D, Wangchuck K, Price RN, Auburn S. 2020.
658   Implementing parasite genotyping into national surveillance frameworks: feedback from control
659   programmes and researchers in the Asia-Pacific region. Malar J 19:271.
660   27.   Fola AA, Harrison GLA, Hazairin MH, Barnadas C, Hetzel MW, Iga J, Siba PM, Mueller I, Barry AE.
661   2017. Higher Complexity of Infection and Genetic Diversity of Plasmodium vivax Than
662   Plasmodium falciparum Across All Malaria Transmission Zones of Papua New Guinea. Am J Trop
663   Med Hyg 96:630-641.
664   28.   Fola AA, Nate E, Abby Harrison GL, Barnadas C, Hetzel MW, Iga J, Siba P, Mueller I, Barry AE.
665   2018. Nationwide genetic surveillance of Plasmodium vivax in Papua New Guinea reveals

heterogeneous transmission dynamics and routes of migration amongst subdivided populations.
Infect Genet Evol 58:83-95.
29.   Waltmann A, Koepfli C, Tessier N, Karl S, Fola A, Darcy AW, Wini L, Harrison GLA, Barnadas C,
Jennison C, Karunajeewa H, Boyd S, Whittaker M, Kazura J, Bahlo M, Mueller I, Barry AE. 2018.
Increasingly inbred and fragmented populations of Plasmodium vivax associated with the
eastward decline in malaria transmission across the Southwest Pacific. PLoS Negl Trop Dis
12:e0006146.
30.   Taylor SM, Parobek CM, Aragam N, Ngasala BE, Martensson A, Meshnick SR, Juliano JJ. 2013.
Pooled deep sequencing of Plasmodium falciparum isolates: an efficient and scalable tool to
quantify prevailing malaria drug-resistance genotypes. J Infect Dis 208:1998-2006.
31.   Nsanzabana C, Djalle D, Guérin PJ, Ménard D, González IJ. 2018. Tools for surveillance of anti-
malarial drug resistance: an assessment of the current landscape. Malaria Journal 17:75.
32.   Duraisingh MT, Curtis J, Warhurst DC. 1998. Plasmodium falciparum: detection of
polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR
and restriction digestion. Exp Parasitol 89:1-8.
33.   Eldin de Pecoulas P, Basco LK, Abdallah B, Dje MK, Le Bras J, Mazabraud A. 1995. Plasmodium
falciparum: detection of antifolate resistance by mutation-specific restriction enzyme digestion.
Exp Parasitol 80:483-7.
34.   Talundzic E, Ravishankar S, Kelley J, Patel D, Plucinski M, Schmedes S, Ljolje D, Clemons B,
Madison-Antenucci S, Arguin PM, Lucchi NW, Vannberg F, Udhayakumar V. 2018. Next-
Generation Sequencing and Bioinformatics Protocol for Malaria Drug Resistance Marker
Surveillance. Antimicrobial Agents and Chemotherapy 62:e02474-17.
35.   Baniecki ML, Faust AL, Schaffner SF, Park DJ, Galinsky K, Daniels RF, Hamilton E, Ferreira MU,
Karunaweera ND, Serre D, Zimmerman PA, Sa JM, Wellems TE, Musset L, Legrand E, Melnikov A,
Neafsey DE, Volkman SK, Wirth DF, Sabeti PC. 2015. Development of a single nucleotide
polymorphism barcode to genotype Plasmodium vivax infections. PLoS Negl Trop Dis
9:e0003539.
36.   Daniels R, Volkman SK, Milner DA, Mahesh N, Neafsey DE, Park DJ, Rosen D, Angelino E, Sabeti
PC, Wirth DF, Wiegand RC. 2008. A general SNP-based molecular barcode for Plasmodium
falciparum identification and tracking. Malar J 7:223.
37.   Fola AA, Kattenberg E, Razook Z, Lautu-Gumal D, Lee S, Mehra S, Bahlo M, Kazura J, Robinson LJ,
Laman M, Mueller I, Barry AE. 2020. SNP barcodes provide higher resolution than microsatellite
markers to measure Plasmodium vivax population genetics. Malar J 19:375.
38.   Daniels RF, Schaffner SF, Wenger EA, Proctor JL, Chang H-H, Wong W, Baro N, Ndiaye D, Fall FB,
Ndiop M, Ba M, Milner DA, Taylor TE, Neafsey DE, Volkman SK, Eckhoff PA, Hartl DL, Wirth DF.
2015. Modeling malaria genomics reveals transmission decline and rebound in Senegal.
Proceedings of the National Academy of Sciences 112:7067-7072.
39.   Taylor AR, Schaffner SF, Cerqueira GC, Nkhoma SC, Anderson TJC, Sriprawat K, Pyae Phyo A,
Nosten F, Neafsey DE, Buckee CO. 2017. Quantifying connectivity between local Plasmodium
falciparum malaria parasite populations using identity by descent. PLOS Genetics 13:e1007065.
40.   Preston MD, Campino S, Assefa SA, Echeverry DF, Ocholla H, Amambua-Ngwa A, Stewart LB,
Conway DJ, Borrmann S, Michon P, Zongo I, Ouédraogo J-B, Djimde AA, Doumbo OK, Nosten F,
Pain A, Bousema T, Drakeley CJ, Fairhurst RM, Sutherland CJ, Roper C, Clark TG. 2014. A barcode
of organellar genome polymorphisms identifies the geographic origin of Plasmodium falciparum
strains. Nature Communications 5:4052.
41.   Trimarsanto H, Amato R, Pearson RD, Sutanto E, Noviyanti R, Trianty L, Marfurt J, Pava Z,
Echeverry DF, Lopera-Mesa TM, Montenegro LM, Tobón-Castaño A, Grigg MJ, Barber B, William
T, Anstey NM, Getachew S, Petros B, Aseffa A, Assefa A, Rahim AG, Chau NH, Hien TT, Alam MS,

Khan WA, Ley B, Thriemer K, Wangchuck S, Hamedi Y, Adam I, Liu Y, Gao Q, Sriprawat K, Ferreira
MU, Barry A, Mueller I, Drury E, Goncalves S, Simpson V, Miotto O, Miles A, White NJ, Nosten F,
Kwiatkowski DP, Price RN, Auburn S. 2019. A molecular barcode and online tool to identify and
map imported infection with Plasmodium vivax. bioRxiv
doi:10.1101/776781:776781.

42.   Jacob CG, Thuy-Nhien N, Mayxay M, Maude RJ, Quang HH, Hongvanthong B, Vanisaveth V, Duc
TN, Rekol H, van der Pluijm RW, Von Seidlein L, Fairhurst RM, Nosten FH, Hossain MA, Park N,
Goodwin S, Ringwald P, Chindavongsa K, Newton PN, Ashley EA, Phalivong S, Maude RR, Leang
R, Huch C, Dong LT, Nguyen K-T, Nhat TM, Hien TT, Nguyen H, Zdrojewski N, Canavati SE, Sayeed
AA, Uddin D, Buckee C, Fanello CI, Onyamboko M, Peto T, Tripura R, Amaratunga C, Thu AM,
Delmas G, Landier J, Parker DM, Chau NH, Lek D, Suon S, Callery JJ, Jittamala P,
Hanboonkunupakarn B, Pukrittayakamee S, et al. 2021. Genetic surveillance in the Greater
Mekong Subregion and South Asia to support malaria control and elimination. medRxiv.

43.   Illumina. 2018. AmpliSeq for Illumina Custom and Community Panels: Reference Guide, San
Diego, California, USA.

44.   WHO. 2020. World Malaria Report 2020. World Health Organization, Geneva.

45.   Cortese JF, Caraballo A, Contreras CE, Plowe CV. 2002. Origin and dissemination of Plasmodium
falciparum drug-resistance mutations in South America. J Infect Dis 186:999-1006.

46.   Chenet SM, Akinyi Okoth S, Huber CS, Chandrabose J, Lucchi NW, Talundzic E, Krishnalall K,
Ceron N, Musset L, Macedo de Oliveira A, Venkatesan M, Rahman R, Barnwell JW, Udhayakumar
V. 2016. Independent Emergence of the Plasmodium falciparum Kelch Propeller Domain Mutant
Allele C580Y in Guyana. J Infect Dis 213:1472-5.

47.   Mathieu LC, Cox H, Early AM, Mok S, Lazrek Y, Paquet JC, Ade MP, Lucchi NW, Grant Q,
Udhayakumar V, Alexandre JS, Demar M, Ringwald P, Neafsey DE, Fidock DA, Musset L. 2020.
Local emergence in Amazonia of Plasmodium falciparum k13 C580Y mutants associated with in
vitro artemisinin resistance. Elife 9.

48.   Vreden SG, Jitan JK, Bansie RD, Adhin MR. 2013. Evidence of an increased incidence of day 3
parasitaemia in Suriname: an indicator of the emerging resistance of Plasmodium falciparum to
artemether. Mem Inst Oswaldo Cruz 108:968-73.

49.   Chenet SM, Okoth SA, Kelley J, Lucchi N, Huber CS, Vreden S, Macedo de Oliveira A, Barnwell
JW, Udhayakumar V, Adhin MR. 2017. Molecular Profile of Malaria Drug Resistance Markers of
Plasmodium falciparum in Suriname. Antimicrob Agents Chemother 61.

50.   Rosas-Aguirre A, Erhart A, Llanos-Cuentas A, Branch O, Berkvens D, Abatih E, Lambert P, Frasso
G, Rodriguez H, Gamboa D, Sihuincha M, Rosanas-Urgell A, D'Alessandro U, Speybroeck N. 2015.
Modelling the potential of focal screening and treatment as elimination strategy for Plasmodium
falciparum malaria in the Peruvian Amazon Region. Parasit Vectors 8:261.

51.   Anonymous. 1999. Política Nacional de Medicamentos para el Control de la Malaria en el Perú.
Ministerio de Salud del Perú, Lima, Perú.

52.   Marquino W, MacArthur JR, Barat LM, Oblitas FE, Arrunategui M, Garavito G, Chafloque ML,
Pardave B, Gutierrez S, Arrospide N, Carrillo C, Cabezas C, Ruebush TK, 2nd. 2003. Efficacy of
chloroquine, sulfadoxine-pyrimethamine, and mefloquine for the treatment of uncomplicated
Plasmodium falciparum malaria on the north coast of Peru. Am J Trop Med Hyg 68:120-3.

53.   Aramburú Guarda J, Ramal Asayag C, Witzig R. 1999. Malaria reemergence in the Peruvian
Amazon region. Emerg Infect Dis 5:209-15.

54.   Ruebush TK, 2nd, Neyra D, Cabezas C. 2004. Modifying national malaria treatment policies in
Peru. J Public Health Policy 25:328-45.

55.   Williams HA, Vincent-Mark A, Herrera Y, Chang OJ. 2009. A retrospective analysis of the change
in anti-malarial treatment policy: Peru. Malar J 8:85.

56. Marquino W, Huilca M, Calampa C, Falconi E, Cabezas C, Naupay R, Ruebush TK, 2nd. 2003.
Efficacy of mefloquine and a mefloquine-artesunate combination therapy for the treatment of
uncomplicated Plasmodium falciparum malaria in the Amazon Basin of Peru. Am J Trop Med Hyg
68:608-12.
57. de Oliveira AM, Chavez J, de Leon GP, Durand S, Arrospide N, Roberts J, Cabezas C, Marquino W.
2011. Efficacy and effectiveness of mefloquine and artesunate combination therapy for
uncomplicated Plasmodium falciparum malaria in the Peruvian Amazon. Am J Trop Med Hyg
85:573-8.
58. Anonymous. 2015. Norma téchnica de salud para la atencion de la malaria y malaria grave en el
Peru. Ministerio de Salud Perú, Direccion regional de Salud Loreto, Iquitos, Peru.
59. Rosas-Aguirre A, Speybroeck N, Llanos-Cuentas A, Rosanas-Urgell A, Carrasco-Escobar G,
Rodriguez H, Gamboa D, Contreras-Mancilla J, Alava F, Soares IS, Remarque E, U DA, Erhart A.
2015. Hotspots of Malaria Transmission in the Peruvian Amazon: Rapid Assessment through a
Parasitological and Serological Survey. PLoS One 10:e0137458.
60. Branch O, Casapia WM, Gamboa DV, Hernandez JN, Alava FF, Roncal N, Alvarez E, Perez EJ,
Gotuzzo E. 2005. Clustered local transmission and asymptomatic Plasmodium falciparum and
Plasmodium vivax malaria infections in a recently emerged, hypoendemic Peruvian Amazon
community. Malar J 4:27.
61. Lerch A, Koepfli C, Hofmann NE, Messerli C, Wilcox S, Kattenberg JH, Betuela I, O'Connor L,
Mueller I, Felger I. 2017. Development of amplicon deep sequencing markers and data analysis
pipeline for genotyping multi-clonal malaria infections. BMC Genomics 18:864.
62. Anderson TJ, Haubold B, Williams JT, Estrada-Franco JG, Richardson L, Mollinedo R, Bockarie M,
Mokili J, Mharakurwa S, French N, Whitworth J, Velez ID, Brockman AH, Nosten F, Ferreira MU,
Day KP. 2000. Microsatellite markers reveal a spectrum of population structures in the malaria
parasite Plasmodium falciparum. Mol Biol Evol 17:1467-82.
63. Koepfli C, Mueller I. 2017. Malaria Epidemiology at the Clone Level. Trends Parasitol 33:974-985.
64. Bacon DJ, McCollum AM, Griffing SM, Salas C, Soberon V, Santolalla M, Haley R, Tsukayama P,
Lucas C, Escalante AA, Udhayakumar V. 2009. Dynamics of malaria drug resistance patterns in
the Amazon basin region following changes in Peruvian national treatment policy for
uncomplicated malaria. Antimicrob Agents Chemother 53:2042-51.
65. Sridaran S, McClintock SK, Syphard LM, Herman KM, Barnwell JW, Udhayakumar V. 2010. Anti-
folate drug resistance in Africa: meta-analysis of reported dihydrofolate reductase (dhfr) and
dihydropteroate synthase (dhps) mutant genotype frequencies in African Plasmodium
falciparum parasite populations. Malar J 9:247.
66. Sidhu AB, Valderramos SG, Fidock DA. 2005. pfmdr1 mutations contribute to quinine resistance
and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum. Mol Microbiol
57:913-26.
67. Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, Chy S, Kim S, Ke S, Kloeung N,
Eam R, Khean C, Ken M, Loch K, Bouillon A, Domergue A, Ma L, Bouchier C, Leang R, Huy R, Nuel
G, Barale JC, Legrand E, Ringwald P, Fidock DA, Mercereau-Puijalon O, Ariey F, Menard D. 2017.
A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-
genotype association study. Lancet Infect Dis 17:174-183.
68. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K,
Looareesuwan S, White NJ, Nosten F, Krishna S. 2004. Mefloquine resistance in Plasmodium
falciparum and increased pfmdr1 gene copy number. Lancet 364:438-447.
69. Veiga MI, Dhingra SK, Henrich PP, Straimer J, Gnadig N, Uhlemann AC, Martin RE, Lehane AM,
Fidock DA. 2016. Globally prevalent PfMDR1 mutations modulate Plasmodium falciparum
susceptibility to artemisinin-based combination therapies. Nat Commun 7:11553.

70.　Tessema SK, Hathaway NJ, Teyssier NB, Murphy M, Chen A, Aydemir O, Duarte EM, Simone W,
Colborn J, Saute F, Crawford E, Aide P, Bailey JA, Greenhouse B. 2020. Sensitive, Highly
Multiplexed Sequencing of Microhaplotypes From the Plasmodium falciparum Heterozygome.
The Journal of Infectious Diseases doi:10.1093/infdis/jiaa527.
71.　Jacob CG, Thuy-Nhien N, Mayxay M, Maude RJ, Quang HH, Hongvanthong B, Vanisaveth V, Ngo
Duc T, Rekol H, van der Pluijm R, von Seidlein L, Fairhurst R, Nosten F, Hossain MA, Park N,
Goodwin S, Ringwald P, Chindavongsa K, Newton P, Ashley E, Phalivong S, Maude R, Leang R,
Huch C, Dong LT, Nguyen K-T, Nhat TM, Hien TT, Nguyen H, Zdrojewski N, Canavati S, Sayeed AA,
Uddin D, Buckee C, Fanello CI, Onyamboko M, Peto T, Tripura R, Amaratunga C, Myint Thu A,
Delmas G, Landier J, Parker DM, Chau NH, Lek D, Suon S, Callery J, Jittamala P,
Hanboonkunupakarn B, Pukrittayakamee S, et al. 2021. Genetic surveillance in the Greater
Mekong subregion and South Asia to support malaria control and elimination. eLife 10:e62997.
72.　Henriques G, Hallett RL, Beshir KB, Gadalla NB, Johnson RE, Burrow R, van Schalkwyk DA, Sawa
P, Omar SA, Clark TG, Bousema T, Sutherland CJ. 2014. Directional selection at the pfmdr1, pfcrt,
pfubp1, and pfap2mu loci of Plasmodium falciparum in Kenyan children treated with ACT. J
Infect Dis 210:2001-8.
73.　Cerqueira GC, Cheeseman IH, Schaffner SF, Nair S, McDew-White M, Phyo AP, Ashley EA,
Melnikov A, Rogov P, Birren BW, Nosten F, Anderson TJC, Neafsey DE. 2017. Longitudinal
genomic surveillance of Plasmodium falciparum malaria parasites reveals complex genomic
architecture of emerging artemisinin resistance. Genome Biology 18:78.
74.　Xie SC, Ralph SA, Tilley L. 2020. K13, the Cytostome, and Artemisinin Resistance. Trends in
Parasitology 36:533-544.
75.　Birnbaum J, Scharf S, Schmidt S, Jonscher E, Hoeijmakers WAM, Flemming S, Toenhake CG,
Schmitt M, Sabitzki R, Bergmann B, Frohlke U, Mesen-Ramirez P, Blancke Soares A, Herrmann H,
Bartfai R, Spielmann T. 2020. A Kelch13-defined endocytosis pathway mediates artemisinin
resistance in malaria parasites. Science 367:51-59.
76.　Henrici RC, Edwards RL, Zoltner M, van Schalkwyk DA, Hart MN, Mohring F, Moon RW, Nofal SD,
Patel A, Flueck C, Baker DA, John ARO, Field MC, Sutherland CJ. 2020. The Plasmodium
falciparum Artemisinin Susceptibility-Associated AP-2 Adaptin mu Subunit is Clathrin
Independent and Essential for Schizont Maturation. Mbio 11.
77.　Behrens HM, Schmidt S, Spielmann T. 2021. The newly discovered role of endocytosis in
artemisinin resistance. Medicinal Research Reviews 41:2998-3022.
78.　Sutherland CJ, Henrici RC, Artavanis-Tsakonas K. 2021. Artemisinin susceptibility in the malaria
parasite Plasmodium falciparum: propellers, adaptor proteins and the need for cellular healing.
FEMS Microbiol Rev 45.
79.　Demas AR, Sharma AI, Wong W, Early AM, Redmond S, Bopp S, Neafsey DE, Volkman SK, Hartl
DL, Wirth DF. 2018. Mutations in Plasmodium falciparum actin-binding protein coronin confer
reduced artemisinin susceptibility. Proc Natl Acad Sci U S A doi:10.1073/pnas.1812317115.
80.　Velavan TP, Nderu D, Agbenyega T, Ntoumi F, Kremsner PG. 2019. An alternative dogma on
reduced artemisinin susceptibility: A new shadow from east to west. Proceedings of the National
Academy of Sciences 116:12611-12612.
81.　Sharma AI, Shin SH, Bopp S, Volkman SK, Hartl DL, Wirth DF. 2020. Genetic background and
PfKelch13 affect artemisinin susceptibility of PfCoronin mutants in Plasmodium falciparum. PLoS
Genet 16:e1009266.
82.　Oberstaller J, Zoungrana L, Bannerman CD, Jahangiri S, Dwivedi A, Silva JC, Adams JH, Takala-
Harrison S. 2021. Integration of population and functional genomics to understand mechanisms
of artemisinin resistance in Plasmodium falciparum. International Journal for Parasitology: Drugs
and Drug Resistance 16:119-128.

83. Griffing SM, Mixson-Hayden T, Sridaran S, Alam MT, McCollum AM, Cabezas C, Marquino
Quezada W, Barnwell JW, De Oliveira AM, Lucas C, Arrospide N, Escalante AA, Bacon DJ,
Udhayakumar V. 2011. South American Plasmodium falciparum after the malaria eradication
era: clonal population expansion and survival of the fittest hybrids. PLoS One 6:e23486.
84. Baldeviano GC, Okoth SA, Arrospide N, Gonzalez RV, Sanchez JF, Macedo S, Conde S, Tapia LL,
Salas C, Gamboa D, Herrera Y, Edgel KA, Udhayakumar V, Lescano AG. 2015. Molecular
Epidemiology of Plasmodium falciparum Malaria Outbreak, Tumbes, Peru, 2010-2012. Emerg
Infect Dis 21:797-803.
85. Okoth SA, Chenet SM, Arrospide N, Gutierrez S, Cabezas C, Matta JA, Udhayakumar V. 2016.
Molecular Investigation into a Malaria Outbreak in Cusco, Peru: Plasmodium falciparum BV1
Lineage is Linked to a Second Outbreak in Recent Times. Am J Trop Med Hyg 94:128-31.
86. Recht J, Siqueira AM, Monteiro WM, Herrera SM, Herrera S, Lacerda MVG. 2017. Malaria in
Brazil, Colombia, Peru and Venezuela: current challenges in malaria control and elimination.
Malaria Journal 16:273.
87. Villena FE, Lizewski SE, Joya CA, Valdivia HO. 2021. Population genomics and evidence of clonal
replacement of Plasmodium falciparum in the Peruvian Amazon. Scientific Reports 11:21212.
88. Schmedes SE, Patel D, Kelley J, Udhayakumar V, Talundzic E. 2019. Using the Plasmodium
mitochondrial genome for classifying mixed-species infections and inferring the geographical
origin of P. falciparum parasites imported to the U.S. PLOS ONE 14:e0215754.
89. Hathaway NJ, Parobek CM, Juliano JJ, Bailey JA. 2017. SeekDeep: single-base resolution de novo
clustering for amplicon deep sequencing. Nucleic Acids Research 46:e21-e21.
90. Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJA, Holmes SP. 2016. DADA2: High-
resolution sample inference from Illumina amplicon data. Nature Methods 13:581-583.
91. Henden L, Lee S, Mueller I, Barry A, Bahlo M. 2018. Identity-by-descent analyses for measuring
population dynamics and selection in recombining pathogens. PLoS Genet 14:e1007279.
92. Grande T, Bernasconi A, Erhart A, Gamboa D, Casapia M, Delgado C, Torres K, Fanello C, Llanos-
Cuentas A, D'Alessandro U. 2007. A Randomised Controlled Trial to Assess the Efficacy of
Dihydroartemisinin-Piperaquine for the Treatment of Uncomplicated Falciparum Malaria in
Peru. PLOS ONE 2:e1101.
93. Mangold KA, Manson RU, Koay ES, Stephens L, Regner M, Thomson RB, Jr., Peterson LR, Kaul KL.
2005. Real-time PCR for detection and identification of Plasmodium spp. J Clin Microbiol
43:2435-40.
94. Rovira-Vallbona E, Van Hong N, Kattenberg JH, Huan RM, Hien NTT, Ngoc NTH, Guetens P, Hieu
NL, Mai TT, Duong NTT, Duong TT, Phuc BQ, Xa NX, Erhart A, Rosanas-Urgell A. 2020. Efficacy of
dihydroartemisinin/piperaquine and artesunate monotherapy for the treatment of
uncomplicated Plasmodium falciparum malaria in Central Vietnam. J Antimicrob Chemother
75:2272-2281.
95. Oyola SO, Ariani CV, Hamilton WL, Kekre M, Amenga-Etego LN, Ghansah A, Rutledge GG,
Redmond S, Manske M, Jyothi D, Jacob CG, Otto TD, Rockett K, Newbold CI, Berriman M,
Kwiatkowski DP. 2016. Whole genome sequencing of Plasmodium falciparum from dried blood
spots using selective whole genome amplification. Malar J 15:597.
96. Straimer J, Gnädig NF, Witkowski B, Amaratunga C, Duru V, Ramadani AP, Dacheux M, Khim N,
Zhang L, Lam S, Gregory PD, Urnov FD, Mercereau-Puijalon O, Benoit-Vical F, Fairhurst RM,
Ménard D, Fidock DA. 2015. Drug resistance. K13-propeller mutations confer artemisinin
resistance in Plasmodium falciparum clinical isolates. Science 347:428-31.
97. Miotto O, Sekihara M, Tachibana S-I, Yamauchi M, Pearson RD, Amato R, Gonçalves S, Mehra S,
Noviyanti R, Marfurt J, Auburn S, Price RN, Mueller I, Ikeda M, Mori T, Hirai M, Tavul L, Hetzel
MW, Laman M, Barry AE, Ringwald P, Ohashi J, Hombhanje F, Kwiatkowski DP, Mita T. 2020.

Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on
the island of New Guinea. PLOS Pathogens 16:e1009133.
98.   Ross LS, Dhingra SK, Mok S, Yeo T, Wicht KJ, Kumpornsin K, Takala-Harrison S, Witkowski B,
Fairhurst RM, Ariey F, Menard D, Fidock DA. 2018. Emerging Southeast Asian PfCRT mutations
confer Plasmodium falciparum resistance to the first-line antimalarial piperaquine. Nat Commun
9:3314.
99.   MalariaGEN. 2015. MalariaGEN Plasmodium falciparum Community Project, *on* MRC Centre for
Genomics and Global Health. https://www.malariagen.net/apps/pf/4.0/. Accessed
100.   Jombart T, Devillard S, Balloux F. 2010. Discriminant analysis of principal components: a new
method for the analysis of genetically structured populations. BMC Genet 11:94.
101.   Chang HH, Worby CJ, Yeka A, Nankabirwa J, Kamya MR, Staedke SG, Dorsey G, Murphy M,
Neafsey DE, Jeffreys AE, Hubbart C, Rockett KA, Amato R, Kwiatkowski DP, Buckee CO,
Greenhouse B. 2017. THE REAL McCOIL: A method for the concurrent estimation of the
complexity of infection and SNP allele frequency for malaria parasites. PLoS Comput Biol
13:e1005348.
102.   Weir BS, Cockerham CC. 1984. Estimating F-Statistics for the Analysis of Population Structure.
Evolution 38:1358-1370.
103.   Hedrick PW. 2005. A standardized genetic differentiation measure. Evolution 59:1633-8.
104.   Jost L. 2008. G(ST) and its relatives do not measure differentiation. Mol Ecol 17:4015-26.
105.   Keenan K, McGinnity P, Cross TF, Crozier WW, Prodöhl PA. 2013. diveRsity: An R package for the
estimation and exploration of population genetics parameters and their associated errors.
Methods in Ecology and Evolution 4:782-788.
106.   Jombart T. 2008. adegenet: a R package for the multivariate analysis of genetic markers.
Bioinformatics 24:1403-5.
107.   Jombart T, Ahmed I. 2011. adegenet 1.3-1: new tools for the analysis of genome-wide SNP data.
Bioinformatics 27:3070-1.
108.   Kamvar ZN, Tabima JF, Grunwald NJ. 2014. Poppr: an R package for genetic analysis of
populations with clonal, partially clonal, and/or sexual reproduction. PeerJ 2:e281.
109.   Henriques G, van Schalkwyk DA, Burrow R, Warhurst DC, Thompson E, Baker DA, Fidock DA,
Hallett R, Flueck C, Sutherland CJ. 2015. The Mu subunit of Plasmodium falciparum clathrin-
associated adaptor protein 2 modulates in vitro parasite response to artemisinin and quinine.
Antimicrob Agents Chemother 59:2540-7.
110.   Adams T, Ennuson NAA, Quashie NB, Futagbi G, Matrevi S, Hagan OCK, Abuaku B, Koram KA,
Duah NO. 2018. Prevalence of Plasmodium falciparum delayed clearance associated
polymorphisms in adaptor protein complex 2 mu subunit (pfap2mu) and ubiquitin specific
protease 1 (pfubp1) genes in Ghanaian isolates. Parasit Vectors 11:175.
111.   Martin RE, Marchetti RV, Cowan AI, Howitt SM, Broer S, Kirk K. 2009. Chloroquine transport via
the malaria parasite's chloroquine resistance transporter. Science 325:1680-2.
112.   Sidhu AB, Verdier-Pinard D, Fidock DA. 2002. Chloroquine resistance in Plasmodium falciparum
malaria parasites conferred by pfcrt mutations. Science 298:210-3.
113.   Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB,
Naude B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE. 2000. Mutations in the P.
falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in
chloroquine resistance. Mol Cell 6:861-71.
114.   Nagesha HS, Casey GJ, Rieckmann KH, Fryauff DJ, Laksana BS, Reeder JC, Maguire JD, Baird JK.
2003. NEW HAPLOTYPES OF THE PLASMODIUM FALCIPARUM CHLOROQUINE RESISTANCE
TRANSPORTER (PFCRT) GENE AMONG CHLOROQUINE-RESISTANT PARASITE ISOLATES. The
American Journal of Tropical Medicine and Hygiene Am J Trop Med Hyg 68:398-402.

115. Roepe PD. 2009. Molecular and physiologic basis of quinoline drug resistance in Plasmodium
falciparum malaria. Future Microbiology 4:441-455.
116. Dhingra SK, Redhi D, Combrinck JM, Yeo T, Okombo J, Henrich PP, Cowell AN, Gupta P, Stegman
ML, Hoke JM, Cooper RA, Winzeler E, Mok S, Egan TJ, Fidock DA. 2017. A Variant PfCRT Isoform
Can Contribute to Plasmodium falciparum Resistance to the First-Line Partner Drug Piperaquine.
MBio 8.
117. Hamilton WL, Amato R, van der Pluijm RW, Jacob CG, Quang HH, Thuy-Nhien NT, Hien TT,
Hongvanthong B, Chindavongsa K, Mayxay M, Huy R, Leang R, Huch C, Dysoley L, Amaratunga C,
Suon S, Fairhurst RM, Tripura R, Peto TJ, Sovann Y, Jittamala P, Hanboonkunupakarn B,
Pukrittayakamee S, Chau NH, Imwong M, Dhorda M, Vongpromek R, Chan XHS, Maude RJ,
Pearson RD, Nguyen T, Rockett K, Drury E, Gonçalves S, White NJ, Day NP, Kwiatkowski DP,
Dondorp AM, Miotto O. 2019. Evolution and expansion of multidrug-resistant malaria in
southeast Asia: a genomic epidemiology study. The Lancet Infectious Diseases 19:943-951.
118. Pelleau S, Moss EL, Dhingra SK, Volney B, Casteras J, Gabryszewski SJ, Volkman SK, Wirth DF,
Legrand E, Fidock DA, Neafsey DE, Musset L. 2015. Adaptive evolution of malaria parasites in
French Guiana: Reversal of chloroquine resistance by acquisition of a mutation in
pfcrt. Proceedings of the National Academy of Sciences 112:11672-11677.
119. van der Pluijm RW, Imwong M, Chau NH, Hoa NT, Thuy-Nhien NT, Thanh NV, Jittamala P,
Hanboonkunupakarn B, Chutasmit K, Saelow C, Runjarern R, Kaewmok W, Tripura R, Peto TJ, Yok
S, Suon S, Sreng S, Mao S, Oun S, Yen S, Amaratunga C, Lek D, Huy R, Dhorda M, Chotivanich K,
Ashley EA, Mukaka M, Waithira N, Cheah PY, Maude RJ, Amato R, Pearson RD, Gonçalves S,
Jacob CG, Hamilton WL, Fairhurst RM, Tarning J, Winterberg M, Kwiatkowski DP,
Pukrittayakamee S, Hien TT, Day NP, Miotto O, White NJ, Dondorp AM. 2019. Determinants of
dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in
Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study.
Lancet Infect Dis 19:952-961.
120. Folarin OA, Bustamante C, Gbotosho GO, Sowunmi A, Zalis MG, Oduola AM, Happi CT. 2011. In
vitro amodiaquine resistance and its association with mutations in pfcrt and pfmdr1 genes of
Plasmodium falciparum isolates from Nigeria. Acta Trop 120:224-30.
121. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q. 2000. Mutations in Plasmodium
falciparum cytochrome b that are associated with atovaquone resistance are located at a
putative drug-binding site. Antimicrob Agents Chemother 44:2100-8.
122. Akhoon BA, Singh KP, Varshney M, Gupta SK, Shukla Y, Gupta SK. 2014. Understanding the
mechanism of atovaquone drug resistance in Plasmodium falciparum cytochrome b mutation
Y268S using computational methods. PLoS One 9:e110041.
123. Peters JM, Chen N, Gatton M, Korsinczky M, Fowler EV, Manzetti S, Saul A, Cheng Q. 2002.
Mutations in cytochrome b resulting in atovaquone resistance are associated with loss of fitness
in Plasmodium falciparum. Antimicrob Agents Chemother 46:2435-41.
124. Griffing SM, Viana GM, Mixson-Hayden T, Sridaran S, Alam MT, de Oliveira AM, Barnwell JW,
Escalante AA, Povoa MM, Udhayakumar V. 2013. Historical shifts in Brazilian P. falciparum
population structure and drug resistance alleles. PLoS One 8:e58984.
125. Costa GL, Amaral LC, Fontes CJF, Carvalho LH, de Brito CFA, de Sousa TN. 2017. Assessment of
copy number variation in genes related to drug resistance in Plasmodium vivax and Plasmodium
falciparum isolates from the Brazilian Amazon and a systematic review of the literature. Malar J
16:152.
126. Basco LK, Ringwald P. 2000. Molecular epidemiology of malaria in Yaounde, Cameroon. VI.
Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate

1001   synthase gene and in vitro resistance to pyrimethamine and cycloguanil. The American journal
1002   of tropical medicine and hygiene Am J Trop Med Hyg Am J Trop Med Hyg 62:271-276.
1003   127.   Hyde JE. 2007. Drug-resistant malaria – an insight. The FEBS Journal 274:4688-4698.
1004   128.   Staines HM, Burrow R, Teo BH-Y, Chis Ster I, Kremsner PG, Krishna S. 2017. Clinical implications
1005   of Plasmodium resistance to atovaquone/proguanil: a systematic review and meta-analysis.
1006   Journal of Antimicrobial Chemotherapy 73:581-595.
1007   129.   Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, Almagro-Garcia J, Neal AT, Sreng
1008   S, Suon S, Drury E, Jyothi D, Stalker J, Kwiatkowski DP, Fairhurst RM. 2017. Genetic markers
1009   associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in
1010   Cambodia: a genotype-phenotype association study. Lancet Infect Dis 17:164-173.
1011   130.   Reed MB, Saliba KJ, Caruana SR, Kirk K, Cowman AF. 2000. Pgh1 modulates sensitivity and
1012   resistance to multiple antimalarials in Plasmodium falciparum. Nature 403:906-909.
1013   131.   Pickard Amy L, Wongsrichanalai C, Purfield A, Kamwendo D, Emery K, Zalewski C, Kawamoto F,
1014   Miller RS, Meshnick Steven R. 2003. Resistance to Antimalarials in Southeast Asia and Genetic
1015   Polymorphisms in pfmdr1. Antimicrobial Agents and Chemotherapy 47:2418-2423.
1016   132.   Mbaye A, Dieye B, Ndiaye YD, Bei AK, Muna A, Deme AB, Yade MS, Diongue K, Gaye A, Ndiaye
1017   IM, Ndiaye T, Sy M, Diallo MA, Badiane AS, Ndiaye M, Seck MC, Sy N, Koita O, Krogstad DJ,
1018   Nwakanma D, Ndiaye D. 2016. Selection of N86F184D1246 haplotype of Pfmrd1 gene by
1019   artemether-lumefantrine drug pressure on Plasmodium falciparum populations in Senegal.
1020   Malar J 15:433.
1021   133.   Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price RN,
1022   Martensson A, Rosenthal PJ, Dorsey G, Sutherland CJ, Guerin P, Davis TM, Menard D, Adam I,
1023   Ademowo G, Arze C, Baliraine FN, Berens-Riha N, Bjorkman A, Borrmann S, Checchi F, Desai M,
1024   Dhorda M, Djimde AA, El-Sayed BB, Eshetu T, Eyase F, Falade C, Faucher JF, Froberg G,
1025   Grivoyannis A, Hamour S, Houze S, Johnson J, Kamugisha E, Kariuki S, Kiechel JR, Kironde F,
1026   Kofoed PE, LeBras J, Malmberg M, Mwai L, Ngasala B, Nosten F, Nsobya SL, Nzila A, Oguike M,
1027   Otienoburu SD, Ogutu B, et al. 2014. Polymorphisms in Plasmodium falciparum chloroquine
1028   resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect
1029   treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-
1030   amodiaquine. Am J Trop Med Hyg 91:833-43.
1031   134.   Dahlstrom S, Ferreira PE, Veiga MI, Sedighi N, Wiklund L, Martensson A, Farnert A, Sisowath C,
1032   Osorio L, Darban H, Andersson B, Kaneko A, Conseil G, Bjorkman A, Gil JP. 2009. Plasmodium
1033   falciparum multidrug resistance protein 1 and artemisinin-based combination therapy in Africa. J
1034   Infect Dis 200:1456-64.
1035   135.   Bopp S, Magistrado P, Wong W, Schaffner SF, Mukherjee A, Lim P, Dhorda M, Amaratunga C,
1036   Woodrow CJ, Ashley EA, White NJ, Dondorp AM, Fairhurst RM, Ariey F, Menard D, Wirth DF,
1037   Volkman SK. 2018. Plasmepsin II-III copy number accounts for bimodal piperaquine resistance
1038   among Cambodian Plasmodium falciparum. Nat Commun 9:1769.
1039   136.   Dharia NV, Plouffe D, Bopp SE, Gonzalez-Paez GE, Lucas C, Salas C, Soberon V, Bursulaya B,
1040   Kochel TJ, Bacon DJ, Winzeler EA. 2010. Genome scanning of Amazonian Plasmodium falciparum
1041   shows subtelomeric instability and clindamycin-resistant parasites. Genome Res 20:1534-44.

1042

1043

1044   **Tables**

1045   **Table 1. Genes of interest for drug resistance molecular surveillance of malaria in Peru.**

Gene ID	Chromosome	Gene with resistance-associated SNP(s)	Drug associated with resistance*
PF3D7_1218300	12	*ap2-mu*	ART (72, 76, 109, 110); QN (109)
PF3D7_1251200	12	*coronin*	DHA (79, 81)
PF3D7_0709000	7	*crt*	CQ (111-115); PPQ (98, 116-119); AMQ (120)
mal_mito_3	mitochondrial	*cytochrome B*	ATQ (121-123)
PF3D7_0417200	4	*dhfr*	PYR (64, 83, 124-127); PG (128)
PF3D7_0810800	8	*dhps*	SULF (64, 83, 124, 125, 127)
PF3D7_1362500	13	*exonuclease*	PPQ (129)
PF3D7_1343700	13	*k13*	ART (9, 46)
PF3D7_0523000	5	*mdr1*	CQ (130, 131); PPQ (69); MQ (68), QN, HF, ART (64, 66, 68, 69, 125, 132); AMQ (69, 120); LF (132, 133)
PF3D7_0112200	1	*mrp1*	ART, MQ, LF (69, 134)
PF3D7_1408000	14	*plasmepsin II*	PPQ (67, 129, 135)
PF3D7_API04900	apicoplast	*23s rRNA*	CM (136)
PF3D7_0104300	1	*ubp-1*	ART (72, 75, 109, 110)

1046   *AMQ: amodiaquine; ART: artesunate; ATQ: atovaquone; CM: clindamycin; CQ: chloroquine; DHA: dihydroartemisinin; HF:*
1047   *halofantrine; LF: lumefantrine; MQ: mefloquine; PG: proguanil; PPQ: piperaquine; PYR: pyrimethamine; SULF: sulfadoxine; QN:*
1048   *quinine. *The list of drugs to which resistance has been observed is non-exhaustive. Validated mutations are listed in the WHO*
1049   *Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019) (7)*

Table 2. Barcode multilocus lineage characteristics. ML lineages were identified, clustered using genetic distance between barcodes with the poppr package in R, and given a number as identifier. Heterozygote genotypes in the barcode were included, resulting in the creating of some mixed clones barcodes, which include lineages in other lineages. Lineage 29 and 95 are in fact the same as lineage 155, with additional minor clones.

	Barcode multilocus lineage	2003-2005			2008-2012		2014-2018			variants of interest for drug resistance							HRP2/HRP3 both deleted (RDT failure)
		unknown district	Belen	San Juan Bautista	Punchana	San Juan Bautista	Mazan	San Juan Bautista	Pastaza	dhfr	dhps	crt	mdr1	coronin	K13	ubp1 - category	
53	GGTGTCTATCTCATCGC GGGGTTTCATC	0	1	19	0	0	0	0	0	single_ mutant	wt	CVMNT	NDFCDD	V424I	K189T	Q107L and/or K1193T variant	no
142	GGTGTCTATTTCGGTTAG GAGTTTCATC	0	0	19	0	0	0	0	0	single_ mutant	single_syn_ mutant_540	CVMNT	NDFCDD	V424I	K189T	R1133S variant	no
148	AGTGTCCGTCCAATCGC GGGATTTTTTC	0	0	16	0	0	0	0	0	double_ mutant	wt	SVMNT	NGFSDD	wt	wt	R1133S variant	no
141	GGCGCCCGTCCAATCGC CGGATTACTACC	0	0	10	0	0	0	0	0	double_ mutant	double_mut ant	SVMNT	NDFCDY	wt	K189T	R1133S + E1011K variant	no (9)/**yes (1)**
124	GGTGCCCGTCCCATCGC CGGATTTTTTC	0	0	3	0	0	0	0	0	double_ mutant	double_mut ant/triple_m utant	SVMNT	NDFCDY	V424I/ wt	wt	Q107L and/or K1193T variant	no
140	GGTGTCTATCTCATCGC GGGACTTCATC	0	0	3	0	0	0	0	0	single_ mutant	wt	CVMNT	NGFSDD	V424I	K189T	Q107L and/or K1193T variant	no
146	GGTXXCTATCTCATCGXG GGGCTTCATC	0	0	2	0	0	0	0	0	single_ mutant	wt incomplete	CVMNT	mixed	V424I	wt incompl ete	Q107L and/or K1193T variant	no
161	GGTGCCCXTCCCATCGC CGGATTATTACC	0	0	2	0	0	0	0	0	double_ mutant	double_mut ant/triple_m utant	SVMNT	NDFCDY	V424I/ wt	K189T		no
62	GGCGCCTATCTCATCGC GGGATTTTACC	0	0	1	0	0	0	0	0	single_ mutant	wt	CVMNT	NDFCDY	V424I	K189T		no
63	GGCGCCTATCTAATXGC CGGATTATNATC	0	0	1	0	0	0	0	0	single_ mutant	incomplete_ mut	CVMNT	mixed	V424I	K189T	mixed	
100	GGXGXCTGXCCXGGXNC XGGATTANTANC	0	0	1	0	0	0	0	0	single_ mutant	incomplete_ mut	CVMNT	NDFCDD	V424I	K189T	mixed	no
104	GGXGXCTATCTXGGTTXX GAGTTCCACT	0	0	1	0	0	0	0	0	single_ mutant	wt	CVMNT	NDFCDD	V62M	K189T	R1133S variant	no

ID	Sequence																	
119	GGXXXCTXTNTXNTNGXXXXGTTXCXTC	0	0	1	0	0	0	0	0		single_mutant		NDFCDD	V424I	G449C	incomplete only wt	no
121	GGXXXCCGTTTXATTGXXGGATTACCACC	0	0	1	0	0	0	0	0	double_mutant	wt	SVMNT	NGFSDD	V62M	K189T	R1133S variant	no
131	GAXAXTTAXCCXGGCTXXGAACTATCATT	0	0	1	0	0	0	0	0	wt	wt	CVMNT	NDFSDD	V62M	wt incomplete	R1133S + E1011K variant	no
133	GXXGXCTAXTTXATCGNXGGGTTTCATC	0	0	1	0	0	0	0	0	single_mutant	wt	CVMNT	NDFCDD	V424I	K189T	incomplete only wt	no
136	GXXXXCTAXTTXGTTXXXGAGXTCCAXC	0	0	1	0	0	0	0	0		wt incomplete	CVMNT	incomplete	V62M	wt incomplete	incomplete only wt	**yes**
144	XGTXCXTXTXXCXTCTXCXGATTAXCXTC	0	0	1	0	0	0	0	0	incomplete_mutant	double_mutant		incomplete	wt	wt incomplete		no
162	XACXCXTXTXTCXGTTXGXAGCTAXCXTT	0	0	1	0	0	0	0	0	single_mutant	single_syn_mutant_540		NG_SDD	V62M			no
163	XAXXXCNXTTXXNTTTXGXAGTTXTXTC	0	1	0	0	0	0	0	0	wt	wt incomplete		mixed	V62M	wt incomplete	incomplete only wt	no
157	GGCGCCTATCCCATCGCCGGGTTACTACC	0	0	29	0	2	0	0	0	single_mutant	wt	SVMNT	NDFCDD	V424I	K189T	Q107L and/or K1193T variant	no
46	GGTGCCTATTTAGTTGAGGAGTTACCACC	1	0	22	1	3	0	0	0	single_mutant	single_mutant/wt	CVMNT	NGFSDD	V62M	K189T	Q107L and/or K1193T variant	**yes**
158	GGCGXCCGTCCXATCGXCGXATTACTTTC	0	0	2	1	0	0	0	0	double_mutant/triple_mutant	double_mutant	SVMNT	NDFCDY	V424I/wt	K189T	R1133S + E1011K variant	**yes (2)** / no (1)
155	GGCGCCCATCTAATCGCCGGATTACTTTC	0	0	0	24	0	11	21	0	triple_mutant	triple_mutant	SVMNT	NDFCDY	V424I (and 1 wt)	K189T/wt(1)	R1133S + E1011K variant	**yes (51)**/no(4)
29	NNCGCCCATCTAATCGCCGGATTACTTTC	0	0	0	11	0	0	0	0	triple_mutant	triple_mutant	SVMNT	NDFCDY	V424I	K189T/wt(1)	R1133S + E1011K variant	no
95	GGCGCCNATCTAATCGCCGGATTACTTTC	0	0	0	3	0	0	0	0	triple_mutant	triple_mutant	SVMNT	NDFCDY	V424I	K189T		**yes**

Running title: Pf AmpliSeq assay for malaria molecular surveillance

ID	Sequence																
14	AACGTCCGTCCAATCGCGGGATTACTTCC	0	0	0	16	2	0	2	0	triple_mutant	triple_mutant	SVMNT	NDFCDY	wt	wt/K189T(2)	R1133S + E1011K variant	no
130	GACGTCCATCCAATCGCGGGATTACTTTC	0	0	0	2	0	0	0	1	triple_mutant	triple_mutant	SVMNT	NDFCDY	V424I/wt	K189T/wt	R1133S + E1011K variant	no (2)/**yes (1)**
7	AACGTCCATCTAATCGCGGGATTACTTTC	0	0	0	1	0	0	2	0	triple_mutant	triple_mutant	SVMNT	NDFCDY	V424I	wt/G449C	R1133S + E1011K variant	no
57	GGNGCCNATTTAATTGCGGAGTTACCACC	0	0	0	0	1	0	0	0		single_mutant	CVMNT/SVMNT	NGFSDD	V62M	K189T	mixed	**yes**
132	GAXXXCCATCTXATCGCXGGATTACTTTC	0	0	0	1	0	0	0	0	triple_mutant	triple_mutant	SVMNT	NDFCDY	V424I	K189T		no
149	GGCGCCCGTCCAATTGCGGAGTTACCACC	0	0	0	0	0	0	0	3	triple_mutant	wt	SVMNT	NDFCDY	wt	K189T	Q107L and/or K1193T variant	no
109	GGCGCCCGTCTAATTGAGGGATTACTTTC	0	0	0	0	0	0	2	0	triple_mutant	triple_mutant	SVMNT	NDFCDY	wt	K189T(1)/wt(1)	R1133S + E1011K variant	no
24	AXXXXCCNXCCXATCNXXGGATTACTTCC	0	0	0	0	0	1	0	0	triple_mutant	incomplete_mut	SVMNT	NDFCDY	V424I	wt incomplete	R1133S + E1011K variant	no
58	GGCGTCCATTTAATTGCCGGATTACTATC	0	0	0	0	0	0	0	1	triple_mutant	triple_mutant	SVMNT	NDFCDY	wt	K189T	R1133S + E1011K variant	no
59	GGCGNCCNTCTAATXGCNGGATTACTTNC	0	0	0	0	0	0	1	0	triple_mutant	triple_mutant	SVMNT	NDFCDY	V424I	K189T	R1133S + E1011K variant	no

1050   **Table 3. Haplotype frequencies in ART and partner drug resistance associated genes.**

			2003-2005		2008-2012		2014-2018		χ^2 p-value
			n/n$_{tot}$	% (95%CI)	n/n$_{tot}$	% (95%CI)	n/n$_{tot}$	% (95%CI)	
ART	*K13*	G449C*	1/141	0.7% (0.1-4.9)	0/68	0%	1/45	2.2% (0.3-73.4)	0.03621
		K189T	94/141	66.7% (58.4-74.0)	42/68	61.8% (49.6-73.6)	25/45	55.6% (40.7-73.4)	
		wt	15/141	10.6% (6.5-17.0)	16/68	23.5% (14.9-73.6)	3/45	6.7% (2.1-73.4)	
		wt incomplete	29/141	20.6% (14.6-28.1)	10/68	14.7% (8.0-73.6)	14/45	31.1% (19.2-73.4)	
		missing	2/141	1.4% (0.4-5.6)	0/68	0%	2/45	4.4% (1.1-73.4)	
	ubp1	Q107L and/or K1193T type	60/141	42.6% (34.6-50.9)	6/68	8.8% (4.0-18.4)	3/45	6.7% (2.1-19.0)	< 2.2e-16
		R1133S type	21/141	14.9% (9.9-21.8)	7/68	10.3% (4.9-20.2)	1/45	2.2% (0.3-14.6)	
		R1133S + E1011K type	33/141	23.4% (17.1-31.2)	53/68	77.9% (66.4-86.3)	41/45	91.1% (78.3-96.7)	
		mixed Q107L/K1193T+ R1133S	3/141	2.1% (0.7-6.4)	1/68	1.5% (0.2-9.9)	0/45	0	
		wt or *wt* incomplete	24/141	17.0% (11.6-24.2)	1/68	1.5% (0.2-9.9)	0/45	0	
	coronin	V424I	78/141	55.3% (47.0-63.4)	41/68	60.3% (48.2-71.3)	37/45	82.2% (68.0-91.0)	0.002743
		V62M	29/141	20.6% (14.6-28.1)	5/68	7.4% (3.1-16.6)	0/45	0%	
		wt	30/141	21.3% (15.3-28.9)	20/68	29.4% (19.7-41.4)	8/45	17.8% (9.0-32.0)	
		mixed	0/141	0%	1/68	1.5% (0.2-9.9)	0/45	0%	
		incomplete	4/141	2.8% (1.1-7.4)	1/68	1.5% (0.2-9.9)	0/45	0%	
SP	*dhfr*	single mutant (S108N)	98/141	69.5% (61.4-76.6)	6/68	8.8% (4.0-18.4)	0/45	0%	< 2.2e-16
		double mutant + BR + I164L	32/141	22.7% (16.5-30.4)	0/68	0%	0/45	0%	
		triple mutant	0/141	0%	61/68	89.7% (79.8-95.1)	44/45	97.8% (85.4-99.7)	
		incomplete	3/141	2.1% (0.7-6.4)	0/68	0%	1/45	2.2% (0.3-14.6)	
		missing	6/141	4.3% (1.9-9.2)	1/68	1.5% (0.2-9.9)	0/45	0%	
	dhps	Single mutant K540K	16/141	11.3% (7.0-17.8)	0/68	0%	0/45	0%	< 2.2e-16
		Single mutant A437G	3/141	2.1% (0.7-6.4)	1/68	1.5% (0.2-9.9)	0/45	0%	
		Double mutant	14/141	9.9% (5.9-16.1)	0/68	0%	0/45	0%	
		triple mutant	2/141	1.4% (0.4-5.6)	48/68	70.6% (58.6-80.3)	30/45	66.7% (51.6-79.0)	
		incomplete mutant	7/141	5.0% (2.4-10.1)	13/68	19.1% (11.4-30.4)	12/45	26.7% (15.7-41.6)	
		wt	80/141	56.7% (48.4-64.7)	4/68	5.9% (2.2-14.8)	2/45	4.4% (1.1-16.4)	
		wt incomplete	19/141	13.5% (8.7-20.2)	2/68	2.9% (0.7-11.2)	1/45	2.2% (0.3-14.6)	
CQ and MQ	*crt* (positions 72-76)	CVMNT	65/141	46.1% (38.0-54.4)	2/68	2.9% (0.7-11.2)	0/45	0%	8.37E-16
		SVMNT	49/141	34.8% (27.3-43.0)	60/68	88.2% (78.0-94.1)	32/45	71.1% (56.1-82.6)	
		CVMNT/SVMNT mixed	0/141	0%	1/68	1.5% (0.2-9.9)	0/45	0%	
		incomplete	27/141	19.1% (13.4-26.6)	5/68	7.4% (3.1-16.6)	13/45	28.9% (17.4-43.9)	
	mdr1 (positions 86, 144, 184, 1034,1042, 1246)	NDFCDD	61/141	43.3% (35.3-51.6)	1/68	1.5% (0.2-9.9)	0/45	0%	< 2.2e-16
		ND_CDD	2/141	1.4% (0.4-5.6)	0/68	0%	0/45	0%	
		NDFCDY	17/141	12.1% (7.6-18.6)	60/68	88.2% (78.0-94.1)	42/45	93.3% (81.0-97.9)	
		NGFSDD	43/141	30.5% (23.4-38.6)	5/68	7.4% (3.1-16.6)	0/45	0%	
		NG_SDD	4/141	2.8% (1.1-7.4)	0/68	0%	0/45	0%	
		NDFSDD	1/141	0.7% (0.1-4.9)	0/68	0%	0/45	0%	
		mixed	5/141	3.5% (1.5-8.3)	0/68	0%	0/45	0%	
		incomplete	8/141	5.7% (2.8-11.0)	2/68	2.9% (0.7-11.2)	3/45	6.7% (2.1-19.0)	

*1/2 G449C also accompanied with K189T; both cases mixed inf.
dhps double mutant (A437G
+A581G)
dhps triple mutant (A437G +A581G + K540E)
wt = wilde type
note: The *ubp1*-haplotype with R1133S and E1011K was frequently observed with additional SNP mutations (K764N, K774N, D777G) and a large insert (EQKY) between amino acid positions 2826/2827.

1051

Figure legends

Figure 1 – Annual *P. falciparum* cases in Peru (black line) from 1992-2020, with first-line treatment policy
changes (source of data: Centro Nacional de Epidemiología, Prevención y Control de Enfermedades (2020)
Sistema de Atención de Solicitudes de Acceso a la Información Pública Vía internet del Ministerio de Salud.
Available at: http://www.minsa.gob.pe/portada/transparencia/solicitud/). Artemisinin combination therapies
were first introduced in the Amazon region in Peru in 2001, contributing to a dramatic decline in cases.
Artesunate mefloquine with primaquine (AS + MQ +PQ) has always been the recommended first-line
treatment in the Amazon region (51) with continued high efficacy (57), and AS+SP was used on the North
Coast. In 2015, AS+MQ+PQ became the recommended first-line treatment in the whole country (58). Peru
reduced malaria case incidence by ≥40% by 2010 using passive case detection (PCD), diagnosis with light
microscopy and treatment with AS+MQ as main components of the control program (59). In 2015, with the
realization that PCD missed asymptomatic infections (60), focal screening and treatment was introduced,
resulting in a further reduction of malaria incidence (50). CQ + PQ = chloroquine + primaquine; SP
= sulfadoxine-pyrimethamine; QN = quinine.

Figure 2 – Map of study sites of retrospective sample collection from the Peruvian Amazon region Loreto
(grey). The majority of samples were collected in Maynas Province (areas 1, 2, and 3): samples collected
in/near the San Juan Bautista district (area 3), which covers part of the urban area of Loreto's capital Iquitos
and peri-urban communities south of Iquitos (n=226), and samples from the Mazán district (area 1; n =17) and
Punchana district (area 2; n =64) with remote communities living near forest rivers such as the Amazon River
and Napo River, North of Iquitos. A final collection of samples from 2018 was available from the Northern
Amazon region in Datem del Marañón Province, Pastaza District (area 4, n=5). *P. falciparum* positive samples
from previous studies were selected based on geographical representation and parasite density (≥100 p/µl by
PCR; geometric mean density 4300±3.1 p/µl).

Figure 3 - Population genetic statistics. A) Genetic diversity (expected heterozygosity, *He*) for each barcode
locus (black dots) grouped by time-period. Boxplots show a decrease in the median [interquartile range] of *He*
after the first time period (2003-2005). Since differences in He might be due to unequal sampling in districts
through time, we assessed He within San Juan Bautista district that was sampled at all three time-periods. This
confirmed decreasing diversity over time, with a pronounced decrease in He in 2014-2018 (p >0.001, Figure S5
and table S10). **B)** Genetic differentiation between the three populations measured as F_{ST} (Weir & Cockerham,
1984) using the R package diveRsity. Number of individuals for each population: $n_{2003-2005} = 118$; $n_{2008-2012} = 65$;
$n_{2014-2018} = 38$. In Figure S5 *He* by time and district is plotted and in Figure S6 the differentiation measures $G`_{ST}$
(Hedrick, 2005) and Jost's D (Jost 2008) are plotted.

Figure 4 - Dynamics of 28-SNP barcode multilocus lineages. Area plot showing the proportions of each ML-
lineage detected in the three different time periods in study samples (n=254) from Peru. ML-lineages were
identified, clustered using genetic distance between barcodes with the poppr package in R, and given an
identifying number. ML-lineages differed by multiple SNPs (≥4 SNPs), enabling lineage classification even when
barcodes had some missing or heterozygous genotypes. Lineages are characterized by unique barcodes and
resistance genotypes and listed in table 2.

Figure 5 - Discriminant analysis of principal components (DAPC). Scatter plot of discriminant analysis (DA)
eigenvalues 1 and 2 using all biallelic SNPs in the core targeted region (excl. amplicons targeting repetitive
regions and non-nuclear targets), showing a differentiation between Peruvian *P. falciparum* samples collected
before 2008 and those afterwards (x-axis, PC1), and a subsequent separation along the y-axis (PC2) from 2014

to more recent years and along geographic distance. SNPs contributing most to the DAPC are listed in Table
S13. DAPC was performed with 40 principal components and 7 discriminants as determined through cross-
validation. The increased resolution in the DAPC allowed the detection of greater genetic variation in isolates
from 2014-2018 (black shapes), compared to lineage analysis.

<u>**List of supplementary material:**</u>

Supplementary files

Supplementary file 1: Variants of interest for drug resistance (.csv)

Supplementary file 2: PF AmpliSeq design: primer sequences and locations on the genome (.xlsx)

Supplementary file 3: Supplementary methods (.docx)

Supplementary file 4: Pairwise linkage disequilibrium (rbarD) and allele loadings for within-country SNP
selection for *P. falciparum* Ampliseq Peru (.xlsx)

1105

Supplementary figures and tables

Figure S1. Distribution of depth of coverage of aligned high quality reads past filter (format field DP) per
amplicon region.

Table S1. Amplicons with low genotype depth.

Table S2. Amplicons with high genotype depth of coverage (>150).

Table S3. Amplicons in conserved regions.

Figure S2. Effect of selective whole genome amplification (sWGA)

Table S4. Error rates in 3D7 replicates without and with sWGA in different subsets of loci.

Table S5. Genotyping known variants in previously genotyped controls

Table S6. Detection limit of variant loci in 3D7-Dd2 mock samples

Table S7. Complexity of infection analyses.

Figure S3. Proportion multiple done infections in Peru.

Table S8. Pairwise comparison of *hrp2/hrp3* classification by PCR and Pf AmpliSeq

Table S9 Barcode SNPs.

Figure S4. Principal component analysis of samples (n=254) collected in Peru between 2003 and 2018.

Figure S5. Expected Heterozygosity by time period and district.

Table S10. p-values for pairwise comparisons of *He.*

Figure S6. Genetic differentiation between parasite populations in the three time periods

Figure S7. Minimum spanning network (nLV graph) of multilocus lineages

Table S11. Linkage disequilibrium

Table S12. 28-SNP barcode loci that become fixed over time

Table S13 Contributions of alleles to DAPC.

Figure S8. Copy number variations in A) plasmepsin II gene (pm2) and B) multidrug resistance gene 1 (mdr1)

Table S14 Cost comparison AmpliSeq vs WGS

Table S15: Laboratory strains included in assay validation

Figure S9. Distributions of log mean depth ratio's for all samples for each *hrp3* amplicon and *hrp2* amplicon

Table S16. Cutoff thresholds for *hrp2* and *hrp3* determination of deletions for each amplicon.

1133